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Generation of foam cells, an essential step for reverse cholesterol transport (RCT) 
studies, uses the technique of receptor dependent macrophage loading with radiolabeled 
acetylated Low Density Lipoprotein (Ac-LDL). In this study, we used the ability of a 
biologically relevant detergent molecule, Lysophosphatidylcholine (Lyso PtdCho), to form 
mixed micelles with cholesterol or cholesteryl ester (CE) to generate macrophage foam 
cells. Fluorescent or radiolabelled cholesterol / Lyso PtdCho mixed micelles were 
prepared and incubated with RAW 264.7 or mouse peritoneal macrophages. Results 
showed that such micelles were quite stable at 4°C and retained the solubilized 
cholesterol during one month storage. Macrophages incubated with cholesterol or CE 
(unlabeled, fluorescently labeled or radiolabeled) / Lyso PtdCho mixed micelles 
accumulated CE as documented by microscopy, lipid staining, labeled oleate 
incorporation, and by thin layer chromatography (TLC). Such foam cells unloaded 
cholesterol when incubated with high density lipoprotein (HDL) and not with oxidized HDL 
(Ox-HDL). We propose that stable cholesterol or CE / Lyso PtdCho micelles would offer 
advantages over existing methods. 
Oxidative stress is associated with heart failure (HF). Previously our research 
group observed that the patients with low left-ventricular ejection fraction showed 
accumulation of high level of oxidized LDL (Ox-LDL) when compared with the heart failure 
patients with normal range of ejection fraction (EF). HDL is known to be atheroprotective 
and one of its important antioxidative functions is to protect LDL from oxidative 
modifications. However, HDL itself undergoes oxidation and Ox-HDL becomes 
functionally poor. It is expected to have a diminished ability to promote reverse cholesterol 
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transport. Therefore, it was hypothesized that the quality of HDL present in the patients 
with EF would more compromised than those present in the patients with normal EF. 
Functionality of HDL was evaluated by measuring its cholesterol efflux capacity from foam 
cells generated in vitro. Functionality of HDL, which is strongly related to the oxidative 
modifications of HDL was further estimated by measuring paraoxonase 1 (PON1) enzyme 
activity associated with HDL. Higher the PON1 activity and RCT ability, better is the 
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CHAPTER 1: GENERAL INTRODUCTION 
Coronary Artery Diseases 
Coronary artery diseases (CAD) are the most common pathobiological 
conditions associated with atherosclerosis (1). CAD is the main cause of death in 
Western societies (2). In United States alone one third of all deaths above the age 
of 35 are caused by CAD. Out of 15 million CAD cases in United States 
approximately 8 million people are known to suffer heart attacks and around half 
a million people die from it every year. Moreover, millions of people suffer from 
severe atherosclerosis without showing any symptoms. The cost to manage CAD 
which includes health care services and loss of productivity of the sufferers could 
build up to more than $100 billion per year (3, 4). 
Atherosclerosis 
The term atherosclerosis (synonymously used with arteriosclerosis) was 
first introduced in 1829 by Jean Lobstein (1). Atherosclerosis is often studied as a 
type of chronic systemic inflammation and is characterized by progressive lesion 
formation and narrowing of arteries. The risk factors associated with 
atherosclerosis are often heritable, known as ‘run in the family’ (5). However, in 
the modern industrialized society atherosclerosis and CAD are more often initiated 
by environmental factors, such as, smoking, obesity, diabetes and lack of physical 
activity. Atherosclerosis is a dynamic process and initiates with the formation of 
fatty streaks on the innermost layer of arterial wall, known as tunica intima. Fatty 
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streaks contain mainly lipid loaded macrophages known as foam cells and other 
immune cells such as T-cells, dendritic cells and mast cells (6). Autopsies of young 
individuals revealed the presence of fatty streaks on the arterial walls which are 
generally asymptomatic (7). These fatty streaks can develop into atheromas over 
the time or can regress with the change in life style, diet and exercise (8). 
Atheroma or atherosclerotic plaques are complex in structure and contain 
lipid laden foam cells, extracellular lipid droplets, mainly cholesterol crystals, 
apoptotic cells and cellular debris in the necrotic core. Plaques are covered by 
smooth muscle cells and collagen-rich matrix to form a fibrous cap (Figure 1) (6). 
Advanced lesions are frequently associated with calcium deposition. Calcification 
of lesions is positively correlated with plaque burden and believed to have a 
protective action against plaque rupture which is often fatal (9). 
Growing plaques can prevent regular blood flow in the coronary artery by 
progressively narrowing the arterial lumen and cause flow-limiting stenosis and 
ischemic conditions. However, the most severe clinical implications are generally 
associated with atherosclerotic plaque rupture. When the fibrous cap is weak or 
damaged, the plaque becomes vulnerable by the action of activated immune cells 
and inflammatory cytokine. Disruption of plaque leads to exposure of thrombogenic 
material located in the core of the plaque, to arterial circulation, resulting in platelet 
aggregation and the formation of thrombus, which eventually can lead to 






Figure 1. Atherosclerotic Plaque Development and Rupture. 
Injury to the tunica intima of endothelial layer of arterial lining initiates plaque formation. 
Accumulation of modified LDL set off a chain reaction that leads to generation of fatty streaks. Fatty 
streaks contain large amount of free and esterified cholesterol, inflammatory immune cells, necrotic 
cells and foam cells. Calcification can stabilize the atheroma, while rupture of plaque leads to 




Low Density Lipoproteins 
Low density lipoproteins (LDLs), the large spherical particles containing 
cholesteryl ester (CE) core, are the major carrier of cholesterol in plasma. Besides 
being the largest pool of CE in the human plasma LDL also contains small amount 
of triglycerides in the neutral lipid core. The highly hydrophobic lipid core is 
surrounded by amphiphilic phospholipids and apolipoprotein B-100 (apo B-100). 
LDLs are derived from triglyceride-rich very-low-density lipoproteins (VLDLs) by 
the action of hepatic lipase. Normally LDL remains in the blood circulation for 2-3 
days (11). About 75% of the LDL particles are absorbed by liver via LDL receptor 
for which apolipoprotein B-100 on the LDL serves as the ligand. Binding of LDL to 
the receptor initiates endocytosis of the particle and fusion of LDL containing 
vesicle to lysosomes, followed by LDL receptor recycling. Lysosomal degradation 
of LDL generates fatty acids, cholesterol, glycerol and amino acids as the primary 
components of LDL. Free cholesterol incorporated in the cytoplasmic cholesterol 
pool is utilized for membrane and steroid synthesis and remaining cholesterol gets 
esterified into highly hydrophobic CE (12). 
Oxidized LDL 
Atherosclerosis is closely associated with the lipid accumulation in the 
tunica intima of the artery. Lipid-laden foam cells, which are found in the 
atherosclerotic plaque, are known to derive its cholesterol burden from LDL (13). 
However, macrophages express limited number of LDL receptors and the 
accumulation of cholesterol in macrophages do not add up to the amount of 
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cholesterol stored via LDL receptor mediated uptake (14), which is also regulated 
by a feedback mechanism (15). LDL are considered to be risk factors for CAD 
because oxidative modification of LDL makes them highly atherogenic. Increased 
plasma level of LDL make them prone to a number of modifications by several 
ways which in turn induce a series of events leading to fatty streak formation. 
Increased plasma level of LDL not only increases intimal LDL level, but also 
causes enhanced adherence of circulating monocytes to the arterial endothelial 
cell lining. Cells found in the atherosclerotic plaque, such as endothelial cells, 
smooth muscle cells, fibroblasts, neutrophils, monocytes and macrophages can 
catalyze the oxidation of LDL. Pro-atherogenic events induced by modified LDL 
are complex. Oxidized LDL (Ox-LDL) recruits monocytes to adhere and penetrate 
the arterial intima by stimulating monocyte chemotactic factor (MCP-1) from the 
endothelial cells. Adherence of monocytes to endothelial cells is associated with 
Ox-LDL stimulated endothelial secretion of intercellular adhesion molecule 1 
(ICAM-1) and vascular adhesion molecule 1 (VCAM-1). Ox-LDL can induce the 
release of macrophage colony stimulating factor (MCSF) which prompts 
differentiation of monocytes into adherent macrophages. Ox-LDL itself can act as 
a chemotactic factor to attract patrolling monocytes. ‘Trapping’ of macrophages in 
the intimal region initiates the fatty streak formation as the scavenger receptors 
(SR) present on the macrophages play a crucial role in cholesterol accumulation. 
Ox-LDL is also believed to cause injury in the endothelial lining of the intima (Fig. 
2) (14, 16). 
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The characteristic feature of modified LDL is the gain of a net negative 
charge which makes them unrecognizable by classical LDL receptors, but converts 
them into ligands for SR present on macrophages. Oxidation of lipid component 
can generate peroxidized lipids which in turn can give rise to aldehydes and leads 
to the alteration of the structure of the protein moiety. Apolipoproteins themselves 
can undergo oxidative modification resulting in cross-linking, proteolysis, structural 
modification and alteration in amino acid compositions of the protein moiety. In 
vitro studies of the oxidative modifications of LDL revealed metal ion such as 
copper, enzyme such as lipoxygenase (Fig. 2), oxygen radicals, reactive nitrogen 
species generated by hydrogen peroxide or myeloperoxidases (17), peroxides and 
superoxides play vital role in the oxidation of LDL and make Ox-LDL recognizable 
by SR (Fig. 2) (18, 19). 
Macrophages and Scavenger Receptors 
Macrophages are commonly associated with innate immune system and 
phagocytosis. In case of atherosclerosis, macrophages play a very critical role in 
the development of plaque mostly due to its unique features associated with 
immune surveillance. During the initiation stage of fatty streak formation, once 
monocytes are recruited and differentiated into macrophages in the intimal region, 
macrophages express a number of SR. SR are cell-membrane proteins and bind 
to a wide variety of ligands including chemically or biologically modified lipoproteins 
(20). In 1979 Goldstein et al. discovered that macrophages utilize their scavenging 
mechanism to uptake modified LDL from plasma. It was also discovered that the 
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macrophage mediated endocytosis of modified LDL takes place via a different 
receptor than the classical LDL receptor (21, 22). Expression of SR are closely 
associated with adherence of cells as fully differentiated macrophages only and 
not the freshly isolated monocytes express high level of SR (23).  
Scavenger Receptor Class A:  
There are two major classes of SR: scavenger receptor class A (SR-A) and 
scavenger receptor class B (SR-B). SR-AI/II (type I and II) are generally present 
on the cell-surface of tissue macrophages such as Kupffer cells and can be 
induced in other cell types (24). Two types of SR-A are derived by alternative 
mRNA splicing and SR-AI is different from SR-AII by having a cysteine–linked C-
terminal extension. SR-A are expressed as transmembrane glycoproteins and the 
collagen like domain form a positively charged groove due to the presence of lysine 
and is involved in the binding of negatively charged ligands (25). They play an 
important role in the phagocytosis of apoptotic cells, in cell adhesion, antigen 
recognition and processing (20). SR-A bind to several polyanionic macromolecules 
such as bacterial surface components- lipopolysaccharides and lipoteichoic acid, 
polyribonucleotides (polyguanosinic acid and polyinosinic acid), dextran sulfate 
and anionic phospholipids such as phosphatidylserine (25). SR-A are also known 
as pattern recognition receptors as they bind to microbial surface proteins of the 
same molecular pattern expressed by a wide range of bacteria (26). SR-A 
expression are regulated by cytokines and atherosclerotic lesions are known to 
have abundant expression of SR-A (25). Initially SR-A were thought to be 
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associated with the binding of acetylated LDL (Ac-LDL). However, as Ac-LDL is 
absent in vivo, the role of SR-A in the endocytosis of Ox-LDL was studied more 
thoroughly (24). It has been suggested that while SR-A are responsible for the 
uptake of 80% and 50% of Ac-LDL and Ox-LDL respectively. Even though its 
efficiency to uptake Ox-LDL is much lesser than that of Ac-LDL, SR-A knockout 
mice showed significant reduction in atherosclerotic lesions in otherwise 
atherosclerotic mice model (20). 
Scavenger Receptor Class B:  
CD36, a member of SR-B family is associated with Ox-LDL uptake. CD36 
along with SR-A are known to be responsible for 75-90% of the uptake and 
degradation of Ac-LDL and Ox-LDL (27). CD36 is an 88-KDa membrane 
glycoprotein and unlike SR-A, it is more ubiquitous in expression. CD36 is 
expressed by adipocytes, skeletal muscle cells, microvascular endothelial and 
smooth muscle cells along with a number of hematocytes such as platelets, 
dendritic cells, monocytes and macrophages (20, 24). Previous studies have 
shown that CD36 can bind to minimally modified LDL (mm-LDL), a form that is 
capable of initiating monocyte migration and “trapping”. In CD36 knockout mice, 
Ox-LDL binding and endocytosis by peritoneal macrophages is known to be 
decreased by 60-80% and the atherosclerotic lesion burden is reduced by 70% 
when CD36- apoE double knockout mice are fed a high-fat diet (20). In human 
subjects lacking CD36, monocyte derived macrophages showed 40% reduction in 
Ox-LDL endocytosis (24). Besides Ox-LDL, the other biologically relevant ligands 
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for CD36 are apoptotic cells, cell debris, Plasmodium falciparum parasitized 
erythrocytes, sickle cell erythrocytes, collagens type I and IV, anionic 
phospholipids and long-chain fatty acids. However, unlike SR-A, CD36 does not 
bind to a host of polyanionic ligands such as fucoidan, polyribonucleic acids and 
carrageenan (20, 24). 
Cholesterol Accumulation and Foam Cells 
Even though the majority of the cholesterol accumulation mediated by 
modified LDL takes place via SR, a number of studies documented different 
sources and pathways of cholesterol accumulation. Blocking of SR-A and SR-B 
together prevented the modified LDL uptake by 75-90%, but could not inhibit the 
cholesterol accumulation completely (28). This observation directed the study to 
understand the unique and not-so-common pathways of foam cell development. 
Kruth et al (29, 30) reported the mechanism for receptor-independent uptake of 
native LDL by macrophages and subsequent development of foam cells. 
According to this model monocyte-derived macrophages upon activation take up 
native and modified LDL by fluid-phase endocytosis, otherwise known as 
macropinocytosis. In this actin-dependent endocytic pathway activated 
macrophages enclose the surrounding fluid within a vacuole by plasma membrane 
fusion and engulf the vacuole to internalize the surrounding fluid. This observation 
was highly valuable as it explains why infectious agents, and inflammatory 
cytokines released from the atherosclerotic plaque induce LDL uptake in its various 
forms (29, 30). Furthermore, macrophages can internalize aggregated LDL, which 
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are too large to fit in the pinocytic vesicles, by phagocytosis (31). Yet another 
model of foam cell development suggests that the presence of sphingomyelinase, 
an enzyme found in arterial wall and in the atherosclerotic lesions, promotes LDL 
receptor mediated native LDL and SR mediated Ac-LDL uptake (32). 
The fundamental mechanisms associated with the foam cell development 
are acyl-CoA: cholesterol O-acyltransferase (ACAT) activation and CE 
accumulation (Fig. 3). Excess of free cholesterol in cells can be highly cytotoxic 
and generally it is converted into CE for storage. Accumulation of cholesterol by 
foam cells is a two-step process: i) lysosome mediated hydrolysis of CE present in 
modified LDL to produce free cholesterol, ii) re-esterification of free cholesterol in 
presence of ACAT to CE as the lipid droplets in the cytoplasm (33). However, the 
studies by Tangirala et al (34, 35) suggested that in the advanced stage of 
atherosclerotic lesion formation lysosome itself can serve as the pool of free 
cholesterol and CE crystals. In older plaques macrophages and smooth muscle 
cells exhibited such cytoplasmic and lysosomal lipid droplet accumulation and 
appeared to be independent of ACAT activation (34, 35). Cholesterol accumulation 








Figure 2. Role of Modified LDL in the Initiation of Fatty Streak Formation. 
Increased plasma concentration of LDL leads to accumulation of LDL in the subendothelial space 
and oxidative modification by 15 lipoxygenase. Ox-LDL acts as a chemoattractant and recruits 
monocytes to differentiate into tissue macrophages. Monocyte adherence to the endothelial layer 
is facilitated by VCAM and ICAM; migration of monocytes to the subendothelial space is achieved 
with the help of MCP-1, Differentiation of monocytes to macrophages is associated with M-CSF. 
Macrophages express scavenger receptors and facilitate the uptake of modified LDL. Cholesterol 
present in the LDL is quickly esterified into CE by the enzyme ACAT and stored as lipid droplets. 






Figure 3. Esterification of Free Cholesterol for storage. 
Free cholesterol which is highly cytotoxic gets converted into highly hydrophobic CE with the help 
of the enzyme ACAT. CE crystals are stored in the cytoplasm and lysosomes of the cells. 
Macrophages are highly efficient in esterification and storage of cholesterol. This reaction is 
reversible and CE is hydrolyzed to produce cholesterol which gets utilized for cell membrane repair 




In Vitro Generation of Foam Cells with Cholesterol Analogue 
Foam cells generated in vitro have been a very important tool to study 
atherosclerotic plaque formation as well as regression. As mentioned earlier, 
generally modified LDL (Ac-LDL and Ox-LDL) are used to generate foam cells. 
Isolated LDL undergoes acetylation or oxidation in presence of acetic anhydride or 
copper ion respectively. To follow the distribution and the fate of the incorporated 
cholesterol, radiolabeled cholesterol (3H or 14C-cholesterol) is often used. In recent 
years fluorescently labeled cholesterol has been used for various studies such as 
to investigate the distribution of cholesterol in cell membrane (36), to understand 
the effects of sterol carrier protein and apolipoprotein E (apoE) on high density 
lipoprotein (HDL) mediated cholesterol efflux (37) and HDL recycling (38), to 
develop high-throughput cholesterol efflux assays (39) and to explore the 
mechanism of cholesterol absorption and storage in the in vivo animal model (40). 
NBD- cholesterol is a commercially available, frequently used fluorescently 
labeled cholesterol analog. NBD group present in the 22-NBD-cholesterol or 22-
(N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino)-23, 24-bisnor-5-cholen-3b-ol, is 
responsible for the fluorescent nature and the excitation wavelength for NBD is 
485 nm. The emission spectra range for NBD varies between 535- 545 nm 
depending on ethanol or aqueous solution respectively (Fig. 4) (41). 
Macrophages, hepatocytes, fibroblasts and lymphocytes have been loaded 
with NBD-cholesterol. Previous studies suggest that NBD-cholesterol can be very 
effectively used to study the cellular uptake and trafficking of the cholesterol. 
However, use of NBD-cholesterol to investigate the distribution of cholesterol in 
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the plasma membrane produced ambiguous results (41). NBD-cholesterol is 







Figure 4. Fluorescent analogue of Cholesterol. 
22-NBD-cholesterol has 22-(N-(7-nitrobenz-2-oxa-1, 3-diazol-4-yl) amino)-23, 24-bisnor-5-cholen-
3b-ol, group attached to cholesterol. It is visualized as green fluorescent probe. The excitation 






Reverse Cholesterol Transport 
In 1968 Glomset (42) proposed the existence of a mechanism which is 
involved in the transport of cholesterol from peripheral tissues to the liver and is 
believed to maintain the cholesterol homeostasis (42). Studies from the last four 
decades have established that Reverse Cholesterol Transport (RCT) is one of the 
most important defense mechanisms of our body to prevent initial plaque 
formation. RCT is a mechanism through which free and esterified cholesterol from 
extrahepatic (peripheral) tissue are effluxed to HDL, travel to liver, and a) get 
secreted as a component of hepatobiliary salt, b) get reabsorbed in small intestine 
as a secretory component in bile or c) get excreted via feces (43, 44). RCT from 
lipid-laden foam cell macrophages are of particular interest because of its 
atheroprotective role. Free cholesterol is utilized by cells for the generation or 
repairment of plasma membrane and for the synthesis of hormones by 
steriodogenic organs. Excess of cholesterol is highly toxic to cells as they cannot 
catabolize cholesterol. However, in macrophages excess of cholesterol can be 
esterified into CE and deposited (45). Macrophages and other peripheral tissues 
efflux excess cholesterol to extracellular acceptors via a number of mechanisms. 
Neutral sterol that is excreted via feces is derived mostly as a by-product of 
cholesterol and bile salt synthesis in liver. Cholesterol effluxed from macrophages 
contributes relatively small amount to this free cholesterol pool. From liver 
cholesterol is delivered to intestine as a component of bile and bile salts and in the 
intestine cholesterol is reabsorbed. Unabsorbed cholesterol along with other 
neutral sterols gets excreted in feces (46). 
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HDL and Apolipoprotein A-I:  
The heterogeneous lipoprotein HDL contains almost equal amounts of lipid 
and protein. Functional HDL is characterized by high hydrated density (1.063-1.21 
g/ml), elevated protein content and small size (5-17 nm) (47). In the total pool of 
HDL, the content of lipid, apolipoproteins and enzymes vary significantly resulting 
in a great diversity in HDL population with different shape, size, density, 
electrophoretic mobility, charge and antigenicity (48). Heterogeneity of HDL is 
determined by its apolipoprotein contents, especially by Apolipoprotein A-I (apoA-
I) conformation. ApoA-I is the major structural apolipoprotein in HDL, constituting 
up to 70% of the total protein content. The amphipathic helical structure of apoA-I 
allows apoA-I associated HDL to switch between discoidal and spherical shape 
under different stages of cholesterol uptake. Ultracentrifugation of HDL gives rise 
to two major fraction-i) less dense, larger HDL2 (1.063-1.125 g/ml) population and 
ii) more dense, smaller HDL3 (1.125-1.21 g/ml) population (49). Generally smaller 
HDL3 is considered to be more effective in inducing cholesterol efflux, shows better 
anti-oxidative and anti-inflammatory properties than larger HDL2. However, a very 
elevated level of HDL3, a condition which can be associated with impaired HDL 
maturation and hepatic delivery of cholesterol, can potentially increase the risk of 
cardiovascular diseases (50). 
The extracellular cholesterol acceptor involved in RCT is essentially HDL in 
different forms. Interaction between lipid-free or lipid-poor apoA-I along with ATP-
binding cassette transporter A1 (ABCA1) initiates the efflux of phospholipids and 
unesterified cholesterol from the cells. Monomolecular apoA-I, which is 
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synthesized by intestine and liver becomes lipidated during this process to form 
pre-β migrating discoidal complex. Pre-β migrating nascent HDL contains at least 
two molecules of apoA-I, bilayer of phospholipids and little unesterified cholesterol 
(Fig. 5). Nascent HDL delivers a portion of its unesterified cholesterol content to 
liver and rest of the free cholesterol is esterified by the action of lecithin: cholesterol 
acyltransferase (LCAT), which is acquired by nascent HDL from blood plasma. 
During the process of highly hydrophobic CE accumulation nascent HDL gets 
converted into spherical α-migrating mature HDL. CE along with small amount of 
triglyceride forms the hydrophobic core of the mature HDL which is surrounded by 
monolayer of phospholipids, unesterified cholesterol and apolipoproteins. A 
portion of CE gets recycled back as the component of newly formed apoB 
containing plasma lipoproteins (LDL and VLDL) with the help of cholesterol ester 
transfer protein (CETP) (51, 52) while majority of CE is delivered to liver (Fig. 6) 
(53). In liver the majority of the cholesterol gets incorporated as a component of 
bile salt and gets secreted in the duodenum to emulsify dietary lipid. A small 
amount of cholesterol is secreted into the bile directly and is re-absorbed by small 
intestine (54). The non-biliary pathway of RCT involves fecal excretion of neutral 
sterols (55). 
Mechanisms Involved in RCT:  
Cholesterol efflux only from macrophages and not the other peripheral 
tissues, are studied as classic RCT model and has significant importance in 
atherosclerotic plaque development. Macrophages present on the arterial wall 
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have the potential to become foam cells as they take up modified lipoproteins and 
apoptotic cells by phagocytosis. Previous studies have indicated that 
macrophages take up more free cholesterol than possibly by any other cells and 
free cholesterol can induce apoptosis in macrophages (56). As mentioned earlier, 
macrophages have two lines of defense against toxicity by excess cholesterol 
loading- i) by esterification of free cholesterol, ii) by cholesterol efflux. Cholesterol 
efflux from macrophages involves various mechanisms, such as transporter or 
receptor associated cholesterol efflux and by passive diffusion. 
ATP-Binding Cassette Transporters:  
ABCA1 play a major role is efflux of free cholesterol from macrophages to 
lipid-poor apoA-I or nascent HDL. ABCA1 is a large integral membrane protein and 
like other members of ABC superfamily utilizes ATP as energy source to transport 
metabolites including lipids across the membrane. Tall et al (57) suggest that the 
membrane domain of ABCA1 binds to apoA-I (57, 58). Close interaction between 
ABCA1 and apoA-I causes transfer of cholesterol and phospholipids from the inner 
plasma membrane leaflet to the outer one by a flopping mechanism (59). ApoA-I 
takes up this cholesterol and phospholipid by absorption and forms nascent HDL 
(57). Several other models have been proposed to explain the high affinity of 
ABCA1 towards nascent HDL. Nonetheless, the importance of ABCA1 in RCT 
mechanism is unquestionable. Tangier disease which is characterized by loss-of-
function mutation in both the ABCA1 alleles, shows severe cholesterol 
accumulation in peripheral macrophages as well as HDL deficiency. In vivo mice 
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models have further established the critical role of ABCA1 in RCT and therefore in 
prevention of atherosclerosis (45, 60). 
ATP-binding cassette transporter G1 (ABCG1) is the other transporter from 
ABC family involved in RCT. However, ABCG1 shows preference for mature HDL 
and not for lipid-poor apoA-I. Disruption of ABCG1 expression results into massive 
cholesterol deposition in peripheral tissues including macrophages (61). Many 
studies suggest that ABCA1 and ABCG1 function cooperatively and the synergistic 
action of these two transporters is responsible for the majority of cholesterol efflux 
from macrophages (62, 63). As expected, when ABCA1 and ABCG1 were knocked 
down simultaneously in the in vitro or in vivo models, cholesterol deposition 
increased severely as the amount of cholesterol efflux was decreased. Increase of 
atherosclerotic plaque formation and decreased rate of RCT were far more evident 
in the cases of dual knock down than the observed in the absence of either of the 
transporters. ABCA1 and ABCG1 are regulated by liver X receptors (LXRα and 
LXRβ) which in turn are strongly regulated by cholesterol levels in plasma (64, 65). 
Role of SR-B1 in RCT:  
Scavenger receptor class B type 1 (SR-B1) is a cell-surface HDL receptor 
which is known to promote cholesterol efflux to mature, spherical α-HDL rather 
than to nascent HDL. Previous studies suggest that the conformation of apoA-I in 
HDL is a strong determinant of SR-B1/ HDL interaction (66). Other studies showed 
SR-B1 mediated free cholesterol efflux is also dependent on the phospholipid 
content of the HDL. SR-B1 mediated cholesterol efflux is markedly increased to 
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the HDL enriched with phosphatidylcholine while HDL enriched with sphingomyelin 
facilitates SR-B1 mediated free cholesterol influx. SR-B1 shows this unique feature 
of facilitating the bidirectional movement of free cholesterol between HDL and 
cells. The bidirectional movement of cholesterol associated with SR-B1 depends 
on the cholesterol concentration gradient between HDL and the plasma membrane 
(66, 67). However, SR-B1 might not play a very crucial role in cholesterol efflux 
from macrophages like ABCA1 and ABCG1 (68) and more investigation is needed 
to fully understand the importance and therapeutic value of SR-B1 in cholesterol 
efflux from atherosclerotic foam cells. 
On the other hand, expression of SR-B1 in liver is extremely crucial for HDL 
metabolism and the maintenance of cholesterol homeostasis. As mentioned 
earlier, SR-B1 facilitates selective uptake of cholesterol from HDL (and other 
lipoproteins) without the degradation of the HDL particle. SR-B1 enables the 
delivery of free, unesterified cholesterol from plasma HDL to liver and 
steroidogenic tissues by a two-step selective uptake mechanism which also 
facilitates the recycling of HDL particles (66). In liver and other tissues HDL binds 
to SR-B1 and cholesterol is efficiently transferred to the cells by diffusion into the 
plasma membrane (69). As expected, overexpression of hepatic SR-B1 is 
associated with lower plasma HDL-cholesterol level and increased content and 
transport of cholesterol into the bile from liver (66). 
The diffusion model of RCT proposed by Johnson et al (70), postulates that 
cholesterol is desorbed from the cell membrane by a spontaneous process and is 
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taken up by HDL molecules. This pathway between the cell membrane and 
acceptor molecule involves diffusion of cholesterol in the aqueous phase (70, 71). 
Current Approaches to Study and Improve RCT:  
RCT is known to be inversely related with the risk of atherosclerotic plaque 
development and cardiovascular diseases. For over a decade efforts have been 
made to quantify RCT and optimize it as a parameter to understand, predict and 
treat the cardiovascular diseases better. Initially in vivo model for RCT was 
developed using mice model. Modified LDL labeled with 3H-cholesterol was utilized 
to generate macrophage foam cells and these foam cells were injected 
intraperitoneally in the recipient mice. Plasma and feces samples were collected 
from these mice at various time points during the experimental duration and the 
fraction of injected 3H-cholesterol recovered in the feces was considered as the 
amount of cholesterol undergoing RCT in a given time starting from macrophages 
(39, 72). For several years this technique has been used to investigate the effect 
of different inhibitors or enhancers on various transporter mediated pathways of 
RCT (73). Radioactive (14C) and fluorescently labeled (40) cholesterol have been 
used for these studies.  Attempts have been made to insert macrophage seeded 
polyethersufone hollow fibers intraperitoneally in animals, to mimic the artery, and 
to study peripheral cholesterol efflux in vivo (74). However, these methods cannot 
be applied to investigate RCT in human subjects. Until recently studying different 
components of RCT in human subjects has been invasive, time-consuming 
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procedures in which hospitalization of patients over a period of time is required to 
administer labeled cholesterol and to collect blood and fecal samples (75, 76). 
Recently attempts have been made to develop the in vitro RCT assay which 
can be used to measure cholesterol efflux from macrophages in presence of 
patients’ serum. Studies by de la Llera-Moya et al (77) and Khera et al (78) used 
macrophages loaded with 3H-cholesterol to measure cholesterol efflux capacity in 
a large patient population. ApoB depleted serum from healthy volunteers or 
patients with different stages of confirmed CAD were used to measure the ability 
of serum HDL to induce cholesterol efflux from the macrophages. The study by de 
la Llera-Moya et al (77) strongly emphasizes the importance of the functionality of 
HDL over the total count of serum HDL. The study by Khera et al (78) which 
integrated all the known transporter, receptor and diffusion mediated cholesterol 
efflux from macrophages, demonstrated that the ability of HDL to induce 
cholesterol efflux was inversely associated with atherosclerosis and CAD. While 
this study reinstated the importance of HDL functionality, it also challenges our 
understanding of RCT and its relationship with HDL in many ways and makes us 
realize that understanding the complexity of RCT is far from over (77, 78). 
Recognizing the key components of RCT and the effort to improve them 
have been important focus for therapeutic approaches to control atherosclerosis 
and CAD. The ex vivo cholesterol efflux assays can be immensely informative 
regarding the roles of ABC transporters in RCT or their regulation by LXR. These 
data can be used to manipulate and develop target-oriented therapeutic approach 
to improve RCT and therefore, reduce the risk of atherosclerosis. Use of LXR 
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agonists to enhance ABC transporters can be potentially beneficial if the 
undesirable hepatic steatosis induced by these agonists can be minimized as a 
side effect. Other approaches explored the possibility to enhance hepatic apoA-I 
expression by using small molecules like RVX-208 or via peroxisome proliferator 
activated receptor α (PPAR α) agonists. Initial human trial studies involving the 
introduction of apoA-I or reconstituted HDL (rHDL) directly in the circulatory system 
showed beneficial effects on RCT and the regression of plaques. Some other 
therapeutic tactics to improve RCT include oral delivery of apoA-I mimetic peptide, 
inhibition of CETP to improve HDL concentration in serum, strategies to increase 
SR-B1 mediated hepatic uptake of cholesterol and direct intestinal secretion of 
cholesterol (79). 
Clinical Relevance of RCT: 
The initial hypothesis regarding linear correlation between HDL 
concentration and risk of developing CAD has been questioned for a long time. 
The importance of cholesterol efflux is undeniable as several preclinical studies 
demonstrated that increased plasma concentration of lipid poor apoA-I not only 
improves RCT, but also attenuates or regresses atherosclerotic plaque formation 
(80). Based on these observations, novel therapeutic models have been proposed 
that will improve the cholesterol efflux capacity of HDL and therefore, HDL 
functionality. However, some recent studies have questioned the relevance of RCT 
itself. A study by Li et al (81), demonstrated that the cholesterol efflux capacity is 
inversely associated with CAD. During this study, initial RCT assays demonstrated 
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that the cholesterol efflux capacity associated with apoB-depleted serum was 
inversely associated with the risk of CAD in the study group. Surprisingly, when 
the same subjects were monitored for the occurrence of CAD for next 3 years, a 
clear inverse relationship between the cholesterol efflux capacity and the 
prevalence of CAD emerged (81). This unique and highly important study once 
again challenges our understanding regarding HDL and its association with CAD. 
Nonetheless, cholesterol efflux from peripheral tissues and atherosclerotic plaques 
is a highly important target to control CAD and more emphasis should be given to 







Figure 5. Formation of HDL through Various Steps. 
ApoA-I is synthesized and secreted by liver and intestine. ApoA-I in the lipid poor form are the best 
acceptors of cholesterol and accept cholesterol via ABCA1. Upon accepting cholesterol, it forms 
discoidal, pre β-migrating nascent HDL which can further accept cholesterol and phospholipid via 
ABCG1, SR-B1 and by diffusion. Esterification of free cholesterol by HDL associated LCAT 
generates spherical, α- migrating, mature HDL. Depending on size, HDL can be divided into small, 
spherical HDL3 and large spherical HDL2. During RCT, ApoA-I is recycled and excess of ApoA-I is 






Figure 6. Reverse Cholesterol Transport. 
Free cholesterol and phospholipids are effluxed from the peripheral tissues or macrophage 
foam cells to HDL via ABCA1, ABCG1, SR-B1 or by diffusion. In HDL, cholesterol is esterified 
into CE by LCAT and transported to the liver by selective uptake through SR-B1. From liver 
cholesterol gets secreted into the bile as the biliary salt component and reaches the intestine. 
Here, cholesterol can get recycled or excreted in the feces. Before reaching the liver, HDL 





HDL and Anti-atherogenicity 
Anti-atherogenic properties of HDL are mainly attributed, but not restricted 
to its capacity to induce cholesterol efflux and reverse cholesterol transport. 
Several studies strongly indicated that HDL prevents oxidation of LDL, enhance 
endothelial function and repairment (53) and thus prevent the initial steps of fatty 
streak formation. HDL is also associated with anti-inflammatory and anti-
thrombotic properties. All properties taken together indicate HDL can prevent 
atherosclerotic plaque progression while promoting lesion regression (53). The 
diverse functionality of HDL is due to the presence of various apolipoproteins, and 
enzymes involved in lipid metabolism, anti-oxidative mechanisms etc. 
Antioxidative Effects of HDL:  
In 1990 Parthasarathy et al described oxidative modification of LDL can be 
reduced or prevented by its co-incubation with HDL (82). Oxidative modification of 
LDL involves oxidation of phospholipids, generation of toxic short-chain aldehydes 
and oxidation of protein moieties resulting in the generation of mm-LDL. Functional 
HDL prevents these modifications by various means. 
ApoA-I prevents or delays the formation of mm-LDL by removal of 
peroxidized fatty acids and phospholipids. Previous studies further indicate that 
HDL can act as a reservoir for peroxidized lipids and deliver them to the liver for 
efficient elimination from the body (83). Other apolipoproteins such as apoE, apoA-
II and apoA-IV are also associated with the anti-oxidant properties of HDL (47). 
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Paraoxonase (PON1), an HDL associated enzyme, plays a crucial role as 
an anti-oxidant and catalyzes hydrolysis of lipid peroxides, fatty acid peroxides and 
hydrogen peroxides to prevent LDL modification (83). PON1, a 45-kDa 
glycoprotein hydrolyzes lactones, organophosphate insecticides and nerve gas 
agents (84). HDL provides a hydrophobic harbor and stabilizes PON1 after its 
secretion from the liver. Association with HDL and interaction with apoA-I is an 
essential step for the proper functioning of PON1 (47). It is considered to be a 
primary contributory factor to the anti-oxidative property of HDL and protects HDL 
from oxidative modification as well. Patients with cardiovascular disorders are 
known to have decreased levels and functionally less active PON1 (85). Oxidized 
phospholipid mediated monocyte chemotaxis and macrophage activation are 
prevented by PON1 (86). Homocysteinylation, a post-translational modification 
that can impair normal protein function, is believed to be neutralized by PON1. 
Homocysteine thiolactone which causes endothelial injury and initiates fatty streak 
formation, is hydrolyzed and detoxified by PON1. Moreover, PON1 is believed to 
enhance the production of Lyso PtdCho and polyunsaturated fatty acids by acting 
like phospholipase A2. It has been hypothesized that Lyso PtdCho improves the 
binding between ABCA1 and HDL and therefore, increases cholesterol efflux (47, 
86). 
Recent investigations suggest accumulation of oxidized lipids is also 
prevented by another HDL associated enzyme LCAT (83). Platelet-activating 
factor-acetyl hydrolase (PAF-AH), glutathione selenoperoxidase (GSPx) are the 
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other HDL-associated enzymes known to have anti-oxidative properties and 
detoxify lipid hydroperoxides to less toxic products (47). 
Anti-inflammatory and Other Anti-atherogenic Function of HDL:  
As mentioned earlier, HDL inhibits monocyte infiltration in the endothelial 
lining induced by Ox-LDL. PON1 and PAF-AH are responsible for this anti-
inflammatory property of HDL. Additionally, HDL prevents the expression of 
cytokine induced cell surface molecules such as VCAM-1, ICAM-1 and E-selectin 
(47, 87), which are essential for the initiation of monocyte transmigration and 
macrophage differentiation. Therefore, HDL reduce inflammatory response 
induced tissue damage. HDL modulates the proper functioning of endothelial cells 
and prevents Ox-LDL induced endothelial cell death. 
Other anti-atherogenic functions attributed to HDL are anti-apoptotic, anti-
thrombotic, vasodilatory, anti-infectious activities (47). 
Dysfunctional HDL and Pro-atherogenicity 
Dysfunctionality of HDL has received tremendous attention in the last two 
decades. A vast amount of researches have been done to identify the factors 
responsible for drastic modifications of structure and composition of HDL and to 
address the outcomes associated with HDL dysfunctionality. Acute-phase 
response, inflammation and oxidative stress render HDL dysfunctional with highly 
adverse consequences.  
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Acute and chronic inflammation is known to reduce the concentration of 
apoA-I in plasma due to decrease synthesis of apoA-I by the liver. Additionally, 
apoA-I is replaced by serum amyloid A (SAA), an acute phase protein, in HDL (47). 
As expected, SAA containing small, dense HDL is far less effective to induce 
cholesterol efflux. Another highly effective way of impairing apoA-I is known to be 
oxidative modifications of certain apoA-I amino acids. Amino acids of apoA-I 
undergo chlorination, nitration modifications by myeloperoxidase, an enzyme 
secreted by arterial wall macrophages. Oxidized apoA-I fails to induce ABCA1 
mediated cholesterol efflux and inhibits LCAT activation (88). 
Under inflammatory conditions or oxidative stress, HDL-associated 
enzymes often become dysfunctional or inactive. During acute phase response, 
PON1 level in plasma is often reduced dramatically or PON1 in HDL is replaced 
by SAA (89). Oxidative stress induced PON1 inactivation is known to be 
associated with elevated hepatic expression of SR (86). Decreased level of PON1 
is closely associated with aging, diabetes and hypercholesterolemia (47). 
Even though modifications of apoA-I and PON1 are mostly responsible for 
the inactivation of HDL, change in the lipid contents of HDL often leads to HDL 
dysfunctionality, other mechanisms contribute significantly to this phenomenon. 
During acute phase response and inflammation, CE present in the core of HDL is 
often replaced by the triglycerides, resulting in decreased plasma HDL levels. This 
characteristic is frequently associated with elevated levels of CETP, which is 




Dysfunctionality of HDL results in reduced cholesterol efflux, decreased 
oxidative protection of LDL by HDL and increased cholesterol influx by 
macrophages. In summary, dysfunctional HDL increases the risk of 
atherosclerosis and cardiovascular diseases by several folds, as opposed to the 
atheroprotective functions of native HDL. 
Heart Failure and Left-ventricular Ejection Fraction 
Heart failure (HF) is one of the costliest and common health problem that is 
complex in nature. The morbidity and mortality rate associated with HF is very high. 
Population studies show that 30-40% of the patients diagnosed with HF, die within 
a year while 60-70% of the mortality happens within 5 years. HF happens following 
the gradual and severe muscle weakness/ stiffening in the heart and inefficient 
pumping of the blood. As the muscle weakness progresses, the organs and 
peripheral tissues receive less amount of oxygenated blood and the pressure in 
the heart gradually increases. 
Ejection fraction (EF) refers to the percent of the total amount of blood in 
the left ventricle, which is pumped out with each heartbeat. A normal heart's EF 
varies between 55-70% and EF below 40% is a strong indicator of HF. EF 60 
indicates that 60% of the total amount of blood from the left ventricle is pumped 
out with each contraction. Patients with EF below 35% are at a very high risk of 
life- threatening irregular heartbeats which can lead to sudden cardiac arrest and 
death. There are 2 types of HF associated with EF: i) Systolic HF or systolic left 
ventricular dysfunction: it is characterized by low left-ventricular EF and less 
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efficient left ventricular contraction resulting in reduced circulation of oxygenated 
blood throughout the body, ii) diastolic HF or HF with preserved left ventricular (LV) 
function: it is characterized by normal left-ventricular EF and normal contraction, 




CHAPTER 2:  
NOVEL TECHNOQUE FOR GENERATING MACROPHAGE FOAM 
CELLS FOR IN VITRO REVERSE CHOLESTEROL TRANSPORT 
STUDIES  
Introduction: 
Increased plasma LDL, an important risk factor for atherosclerosis, leads to 
its sub-endothelial accumulation. In the intima LDL undergoes several structural 
and physiological modifications, mediated by oxidation, denaturation, by enzyme 
actions or by self-aggregation (32, 90-93). Enhanced uptake of modified 
lipoproteins by macrophages involves at least two crucial scavenger receptors, 
namely SR-A1 and CD36 (27, 94). In addition, fluid phase pinocytosis of LDL has 
been suggested to result in foam cell formation (95). Eventually, lesion progression 
and plaque rupture result in platelet aggregation and the formation of thrombus, 
which can lead to heart attack or stroke (96). Changes in lifestyle, diet and physical 
exercise are known to cause regression of atherosclerosis (8). 
RCT is a mechanism through which cholesterol from peripheral tissues, 
especially from macrophage-rich plaques, are effluxed to apoA-I/ HDL, and then 
transferred to liver for disposal (51, 73, 97). It is currently believed that cholesterol 
efflux capacity of HDL, and not the HDL cholesterol level, has positive correlation 
with anti-atherogenicity (98). However, recent studies by Hazen and associates 
showed a remarkable association of RCT with increased risk for myocardial 
infarction, stroke, and death.  Although RCT assay at the time of sample collection 
indicated cholesterol efflux activity from macrophages to apoB-depleted serum, as 
cholesterol acceptor, was inversely associated with risk of prevalent CAD (81), 
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when subjects were followed for three years a positive correlation between 
increased cholesterol efflux and increased CAD was observed.  Regardless of the 
implications of RCT, it is obvious that RCT is an important phenomenon that 
requires not only further investigations but also more efficient methods. Cholesterol 
efflux from peripheral tissues is promoted by transporters, ABCA1 and ABCG1 
(98). RCT also involves uptake of free and esterified cholesterol by hepatic HDL 
receptor SR-B1 (99).  
HDL not only acts as an acceptor for plaque cholesterol (100) but also has 
been suggested to have several anti-atherogenic functionalities, such as anti-
oxidative, anti-inflammatory and anti-thrombotic (53, 87, 101) properties. Oxidation 
of HDL renders it “dysfunctional” (47, 88) and this dysfunctionality has been 
suggested to be an important factor in the control of atherosclerosis. Previous 
studies showed that oxidation of apoA-I impairs the efflux of cholesterol, and 
thereby RCT (102).  
The currently available technique to study RCT in vitro involves the use of 
macrophage foam cells generated by incubation with cholesterol labeled Ac-LDL. 
Macrophages incubated with radiolabeled Ac-LDL are used as foam cells to study 
RCT with respect to HDL heterogeneity (103) and to investigate the role of ABCA1 
in RCT (39, 77). In recent times, a novel approach has been taken for high-
throughput cholesterol efflux studies. Macrophages incubated with radiolabeled 
free cholesterol were utilized to study cholesterol efflux in presence of serum from 
human subjects (78, 81).  Fluorescently labeled cholesterol (NBD-cholesterol), 
which has the NBD probe attached to alkyl chain of cholesterol (104), has been 
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used for several in vitro RCT studies. This method has been extended to study 
RCT in an in vivo model (74). Foam cells loaded with radiolabeled Ac-LDL are 
injected intraperitoneally in animal models, then distribution of labeled cholesterol 
in plasma, liver and feces were followed and measured (40, 73). To understand 
and evaluate the functionality of HDL, a speedier and more reliable assay needs 
to be developed.  
The current methods of labeling Ac-LDL with radioactive or fluorescent tags 
suffer from major deficiencies. First LDL has to be isolated from suitable donors 
and Ac-LDL needs to be prepared. These lipoproteins are inherently unstable and 
their shelf life is limited. Our previous studies have demonstrated that LDL 
undergoes oxidation even during the centrifugation involved in its preparation (90). 
Longer dialysis and other steps also promote oxidation and such particles have to 
be stored with Ethylenediaminetetraacetic acid (EDTA) or other additives. 
Acetylation involves toxic chemicals, such as acetic anhydride, and additional 
dialysis steps are involved in its isolation. The incorporation of 
radioactive/fluorescent tags involves physical adsorption methods and yet another 
purification step to remove unincorporated tracers. In addition, there is variability 
in the extent of cholesterol incorporation into different preparations of Ac-LDL that 
might offer inconsistent information regarding RCT when cholesterol efflux data 
from different patients are compared.  
Thus, there is a need for an efficient method for incorporation of cholesterol 
into macrophages. Past studies from our laboratory demonstrated that a highly 
non-polar molecule, β-carotene, could be very efficiently solubilized using Lyso 
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PtdCho as a natural “detergent”. The resulting solution was optically clear, stable 
and provided an opportunity to enrich cellular β-carotene in a concentration-
dependent manner (105). In this study, we use a similar technique to incorporate 
cholesterol or CE into macrophages to generate foam cells. Lyso PtdCho is very 
efficiently utilized by macrophages by different ways: a) an acyltransferase 
reaction yields Phosphatidylcholine (PtdCho) from lyso, b) lyso phospholipase 
cleaves the acyl ester bond and removes the detergent nature of Lyso PtdCho, 
and c) inter molecular trans-esterification reaction creates a molecule of PtdCho 
and glycerophosphorylcholine (106, 107). In contrast, macrophages esterify 
cholesterol and accumulate CE efficiently (108). Thus, while Lyso PtdCho would 
be “de-toxified”, CE will accumulate. This process also could be considered 
biological as Ox-LDL has been suggested to be involved in foam cell formation, 
and contains substantial levels of Lyso PtdCho (109, 110). 
NBD-cholesterol has been previously used in several studies related to 
uptake, metabolism and HDL-mediated efflux in primary hepatocytes and 
fibroblasts (38, 111). In recent years NBD-cholesterol has become a significant 
tool to study cholesterol metabolism because it closely mimics the behavior of 
cholesterol regarding metabolism and intracellular trafficking (37). In the present 
study NBD-cholesterol along with a 3H-cholesterol have been used as the analogs 
for cholesterol to demonstrate Lyso PtdCho mediated cholesterol loading, foam 
cell development and HDL-induced cholesterol efflux. 
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Materials and Methods: 
Reagents: 
RPMI 1640, Advanced DMEM (ADMEM), fetal bovine serum (FBS), sodium 
pyruvate, L-glutamine, penicillin-streptomycin (PS), 1X phosphate buffer saline 
(PBS), NBD-cholesterol were bought from Invitrogen Life Technologies (Carlsbad, 
CA). Cholesterol, Lyso PtdCho from egg yolk, oleic acid, 0.9% saline, fucoidan, 
polyinosinic acid, 4-dimethylaminopyridine and silica gel matrix for thin layer 
chromatography (TLC) separation were purchased from Sigma-Aldrich (St. Louis, 
MO). Chloroform, methyl alcohol, hexane, diethyl ether, acetic acid isopropyl 
alcohol and ethyl alcohol were purchased from VWR international (Randor, PA).  
[1, 2- 3H (N)] cholesterol, [1-14C] Oleic acid, [methyl-14C] Choline chloride were 
purchased from American Radiolabeled Chemicals (St. Louis, MO). Oil red O was 
purchased from Fisher Scientific (Hampton, NH) and oleic anhydride from Santa 
Cruz biotechnology (Dallas, TX).  
Cell Culture: 
RAW 264.7 macrophages were cultured in RPMI 1640 medium containing 
10% FBS, 1% PS, 1% sodium pyruvate and 1% L-glutamine. Cells were seeded 
at 1.2 X 106/ ml density and incubated at 37° C in a 5 % CO2 incubator to reach 
65-70% confluence overnight. For the experiments involving foam cell 
development RPMI 1640 with 0.1% Lipoprotein deficient serum (LPDS) was used 
as incubation medium. Swiss Webster mice were purchased from Charles River 
(Wilmington, MA) and used to collect peritoneal macrophages. Macrophages from 
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peritoneal cavity of 10-week old Swiss Webster mice were isolated by peritoneal 
lavage using 5 ml cold 0.9% saline, followed by centrifugation. Cells were cultured 
under the same conditions as used for RAW macrophages. HepG2 cells were 
cultured in ADMEM containing 10% FBS, 1% PS and 1% L-glutamine. 
Solubilization of Cholesterol: 
Stock solutions of 5 mM cholesterol and 2 mM NBD-cholesterol were 
prepared in chloroform. 20 mM Lyso PtdCho stock solution was prepared in 
chloroform: methanol (1:1). For a typical reaction 3 µmoles of cholesterol (600 µl 
from the stock), 10 nmoles of NBD-cholesterol (5 µl from the stock) and 3 µmoles 
of Lyso PtdCho (150 µl from the stock) solutions were mixed together in a test 
tube, followed by drying under nitrogen. 1 ml of sterile PBS was added to the dried 
content and the mixture was vigorously vortexed for 1-2 minutes. The aqueous 
solution was filtered through 0.22 µm filter. The entire procedure was done under 
semi-darkness.  
In studies with radioactive cholesterol, NBD-cholesterol was substituted 
with 3H-cholesterol to give a final specific radioactivity of 5000 disintegration per 
minute (DPM)/ nmole of cholesterol.  
Synthesis of Fluorescent CE: 
2 mg cholesterol, 0.2 mg NBD-cholesterol and 25 mg oleic anhydride were 
mixed and dried in a glass tube. 4-dimethylaminopyridine was added to the 
reaction mixture as a catalyst for esterification (112) and the whole reaction mixture 
40 
 
was heated at 80°C for 30 minutes, until the liquid became bright yellow. The 
presence of NBD-CE was verified by TLC and later NBD-CE was separated from 
the reaction mixture by column chromatography. Purity of NBD- CE was checked 
again by TLC. 
Isolation and Modifications of Lipoproteins:  
Following Institutional Review Board approval, blood was collected in 
heparinized tubes from consented healthy donors and stored on ice. Blood was 
centrifuged at 3000 rpm for 20 minutes and plasma was separated. Lipoproteins 
were isolated from normal plasma by sequential ultracentrifugation using a 
Beckman TL-100 tabletop ultracentrifuge (Beckman, Palo Alto, CA) (113). The 
isolated lipoproteins were dialyzed against 0.3 mM EDTA in 1x PBS (pH 7.4) 
overnight and subsequently filter sterilized. The amount of protein was estimated 
using the Folin Lowry method. Lipoprotein sample was subjected to oxidation 
immediately after dialysis. Oxidation of lipoproteins was performed using either 
5µM copper or myeloperoxidase (MPO) as described previously (114, 115). LDL 
was acetylated using acetic anhydride (92). Ac-LDL was dialyzed overnight and 
filter sterilized using 0.2 μm syringe filter. Isolated and modified lipoproteins were 
stored at 4°C and used within 1 week of preparation.  
Tagging Ac-LDL with 3H-cholesterol was done as described previously by 
Kritharides et al (116). Ac-LDL and 3H-cholesterol in ethanol were co-incubated 
with RPMI containing 1% LPDS for 24 hours at 37°C. This stock reaction mixture 
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was diluted to obtain a working solution which contained 10 µg protein/ ml of Ac-
LDL and 0.25 µCi/ ml 3H-cholesterol in RPMI with 0.1% LPDS (116, 117). 
Cellular Uptake of Cholesterol: 
RAW 264.7 macrophages were seeded in 12- well plate at 1.2X106 cells/ml 
concentrations to reach 65-70% confluence overnight. Cells were washed with 
warm sterile PBS once followed by 4 hour of incubation with 0.1% LPDS containing 
RPMI 1640. After 4 hours these cells were incubated with 40 µl of cholesterol or 
CE/ Lyso PtdCho mixed micelle filtrate per ml of medium (equivalent of 120 µM 
concentrations of Lyso PtdCho and cholesterol (or CE) each). For each experiment 
involving cholesterol (unlabeled and NBD or 3H-cholesterol) / Lyso PtdCho mixed 
micelles 40 µM oleic acid was added to the cells during the incubation.  Freshly 
isolated peritoneal macrophages were seeded in 24 - well plate at 2.5X106 cells/ml 
concentrations and used in the same way to demonstrate cholesterol uptake via 
cholesterol / Lyso PtdCho mixed micelles. After overnight incubation, cells were 
washed with warm PBS twice and images of live cells were taken under 
fluorescence microscope (Axio imager, Carl Zeiss AG, Oberkochen, Germany) or 
cells were fixed with 10% formalin and stained with Oil red O.  
Detection of Foam Cells: 
To detect the presence of fluorescent NBD-cholesterol within the cells, 
images of live cells were taken with AxioCam MRm (Axio imager, Carl Zeiss AG, 
Oberkochen, Germany). RAW 264.7 macrophages were then lysed by incubating 
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with 1 ml of methanol at 37°C for 15 minutes. Cell lysates were centrifuged at 3000 
rpm for 10 minutes. 100 µl of supernatant was used to measure fluorescence 
intensity present within the cells. Fluorescence plate reader (Envision 2014 
Multilabel Plate Reader, PerkinElmer, Waltham, MA) was used to measure 
fluorescence intensity at emission spectra of 535 nm upon excitation at 475 nm. 
Macrophages were also fixed to stain for CE droplets. After washing with 
PBS cells were fixed with 10% formalin, made permeable with 60% isopropanol 
and stained with Oil red O. Images of foam cells were taken under 10X and 40X 
objectives in the light microscope with the Leica DFC295 camera (Leica camera 
AG, Solms, Germany). Oil red O stained lipid droplets were further quantified by 
elution of the stain followed by absorption measurement with a spectrophotometer. 
Stained wells were rinsed with 60% isopropanol very briefly to remove any residual 
Oil red O and then dried completely. Stains were eluted with 1 ml isopropanol for 
10 minutes at room temperature. After thorough pipetting to ensure complete 
elution, 100 µl aliquots were taken in triplicates in a 96-well plate and absorbance 
was measured at 500 nm (118).  
Quantification of Cholesterol Incorporated in Total Extracted Lipid and in CE 
Fraction: 
Macrophages were incubated with 3H-cholesterol labeled Ac-LDL or 
cholesterol (unlabeled and 3H-cholesterol) / Lyso PtdCho mixed micelles for 18 
hours at 37°C. Lipid extraction was done using the method of Bligh and Dyer (119). 
Lipids were dissolved in 50 µl of chloroform and 5 µl of this was utilized directly to 
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measure 3H-cholesterol incorporation. This procedure was done in triplicates and 
rest of the reconstituted lipid (~ 35 µl) was used for TLC analysis.  Lipids were 
separated by TLC on silica gel matrix using hexane/ diethyl ether/ acetic acid (30: 
6: 0.5; V/V/V) solvent system (120) and visualized with iodine vapor. Spots of CE 
from samples incubated with 3H-cholesterol labeled Ac-LDL or cholesterol 
(unlabeled and 3H-cholesterol) / Lyso PtdCho mixed micelles were compared with 
CE standard and analyzed for 3H-cholesterol incorporation by liquid scintillation 
and luminescence Counters (MicroBeta2 Plate Counter, PerkinElmer, Waltham, 
MA). Count per minute (CPM) values obtained for the incorporation of 3H-
cholesterol in total extracted lipid or CE fraction of lipid was converted into nmoles 
of cholesterol and represented subsequently. 
Incorporation of 14C- Oleic acid in CE within Foam Cells: 
To demonstrate the conversion of cholesterol into CE while using 
cholesterol/ Lyso PtdCho mixed micelles, 14C- Oleic acid was introduced during 
incubation of cells with cholesterol/ Lyso PtdCho mixed micelles. A stock solution 
of 100 mM oleic acid containing 1 µCi 14C- Oleic acid was prepared. RAW 264.7 
macrophages were incubated with either cholesterol/ Lyso PtdCho or CE/ Lyso 
PtdCho mixed micelles in presence of 40 µM oleic acid/ ml of medium for 18 hours. 
After overnight incubation, cells were washed with warm PBS twice and lipid 
extraction was done with methanol / chloroform (2:1) (119). Chloroform-lipid phase 
was separated, the solvent was evaporated under nitrogen and the lipids were 
reconstituted with chloroform. Lipids were separated and CE was identified as 
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described previously. Spots of CE from samples incubated with cholesterol/ Lyso 
PtdCho or CE / Lyso PtdCho mixed micelles were compared with CE standard and 
analyzed for 14C- Oleic acid incorporation by autoradiography (Cyclone Plus 
Phosphor Imager- PerkinElmer, Waltham, MA) followed by liquid scintillation and 
luminescence counting.    
Measurement of Lactate Dehydrogenase Activity:  
Lactate dehydrogenase (LDH) cytotoxicity assay kit (Catalog number-
10008882) was purchased from Cayman Chemical (Ann Arbor, MI) and the assay 
was performed following the protocol supplied with the kit. In brief, RAW 264.7 
macrophages were seeded at 105 -106 density in 96-well plate. After treating the 
cells for 18 hours, 100 µl of medium was collected from each of the well and NAD+ 
(provided with the kit) was added to the medium. Enzymatic activity of LDH 
oxidized lactate into pyruvate and converted NAD+ into NADPH and H+. Finally, a 
colorimetric reaction between NADPH and H+ and diaphorase (provided with the 
kit) produced dark-pink formazan. Formation of formazan was measured at 490-
520 nm wavelength using a plate-reader (Benchmark Plus Microplate 
Spectrophotometer System, Bio-Rad laboratories, Hercules, CA) and LDH activity 
per ml of medium was calculated using standard curve.  All the treatments were 
performed at least in triplicates and repeated four times.  
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Hemolysis of Human RBC: 
Human blood collected in a heparinized tube was centrifuged at 3000 rpm 
for 20 minutes and red blood cells (RBC) was collected from the pellet and washed. 
RBC was diluted with 0.9% saline (1:20; vol: vol) and hemolysis in presence of 
water was performed to determine the optical density value equivalent to 1 and to 
determine the optimum volume of diluted RBC required for the rest of the 
experiment. 75 µl of diluted RBC was taken in eight glass tubes and 0, 10, 25, 50, 
100, 150, 200 and 250 µM of Lyso PtdCho micelles, cholesterol/ Lyso PtdCho and 
CE/ Lyso PtdCho mixed micelles were added to each tube. The volume was made 
up to 1 ml by adding PBS and the reaction mixtures were incubated at room 
temperature for 15 minutes. Then the reaction mixtures were centrifuged at 2000 
rpm for 15 minutes.  Without disturbing the cell pellet, 100 µl of supernatant from 
each glass tube were taken in triplicates in a 96-well plate and absorbance was 
measured at 540 nm.   
Synthesis of 14C- Lyso PtdCho and Quantification of Lyso PtdCho Metabolism by 
Macrophages: 
Synthesis of 14C- Lyso PtdCho was done from 14C- Choline chloride. HepG2 
cells were incubated with 5 µCi of 14C- Choline chloride in presence of total growth 
medium, ADMEM that contains 4 µg/ ml choline chloride. After 72 hours of 
incubation lipids were extracted and were separated by thin layer chromatography 
using chloroform/ methanol/ water (65: 25: 3.5; V/V/V) as the solvent system. 
PtdCho band was extracted with chloroform: methanol (1: 1) followed by 
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reconstitution of dried lipid content with 0.8 ml of PBS. This reconstituted PtdCho 
was subjected to enzymatic conversion into Lyso PtdCho by adding 25 µl snake 
venom phospholipase A2 (sPLA2) (0.5 units) and 80 µl of 10 mM CaCl2. The 
reaction was set at 37°C for 4 hours and the reaction mixture was used to run TLC 
using the previous solvent system with Lyso PtdCho and PtdCho as standards. 
Lyso PtdCho band from the TLC plate was extracted and was used for further 
experiments. 
14C-Lyso PtdCho was mixed with 3 µmoles unlabeled Lyso PtdCho and 3 
µmoles cholesterol from the previously described stock solutions. The reaction 
mixture was dried under nitrogen and reconstituted with 1ml PBS by vigorous 
vortexing. After filtering, 5 µl the micelles were used to measure radioactivity count. 
Cholesterol/ Lyso PtdCho (unlabeled and 14C labeled) mixed micelles containing 
at least 5000 CPM/ ml activity (~ 25 µl/ ml of medium) were used to incubate RAW 
264.7 macrophages with for 18 hours at 37°C. After overnight incubation lipid 
extraction was done by Bligh and Dyer method and reconstituted lipid was used to 
run TLC with PtdCho and Lyso PtdCho standards using chloroform/ methanol/ 
water (65: 25: 3.5; vol: vol: vol) solvent system. Spots corresponding to PtdCho 
and Lyso PtdCho standards were isolated from the TLC plate and metabolic fate 




Quantification of Cellular Cholesterol Efflux: 
RAW 264.7 macrophages and mouse peritoneal macrophages incubated 
overnight with cholesterol/ Lyso PtdCho mixed micelles were washed with PBS 
twice and fresh medium was added. Cells were then incubated with 0- 200 µg/ml 
of native HDL or 25 and 50 µg/ml of Ox-HDL (MPO or Cu mediated) for 4 hours 
and medium was collected to measure fluorescence intensity. After removal of the 
medium, RAW 264.7 macrophages were washed with PBS and images under 
fluorescence microscope were taken. To measure fluorescence intensity within the 
cells, cell lysates were prepared as described before or cells were fixed and 
stained with Oil red O to observe CE accumulation.  
To study cholesterol efflux, foam cells were also developed using 3H-
cholesterol (and unlabeled cholesterol) / Lyso PtdCho mixed micelles. Efflux of 3H-
cholesterol in medium upon incubation with HDL was measured by liquid 
scintillation and luminescence counters.  
Statistical Analysis: 
Each experiment was performed more than three times and each 
experimental condition was set up in triplicates. All values were presented as mean 
± standard deviation. To determine the difference between two groups, unpaired 
2-tailed Student’s t–test was applied. Analysis of variance (ANOVA) was applied 
with Dunnett’s or Bonferroni’s correction for multiple comparisons using GraphPad 
Prism 5.0 software (San Diego, CA). The minimum level of significance in all tests 




Solubilization of Cholesterol in Aqueous Solution in Presence of Lyso PtdCho: 
Cholesterol was solubilized in PBS by mixing cholesterol and Lyso PtdCho 
together. To determine if Lyso PtdCho could increase the solubility of cholesterol 
in PBS, constant amounts of cholesterol, NBD- cholesterol and an increasing 
amount of Lyso PtdCho were taken in five glass tubes. After drying, vigorous 
mixing and filtering, aqueous solution was made with 1 ml PBS as described in the 
methodology. Prepared mixed micelles contained 1 mM cholesterol (200 µl from 5 
mM stock) and 5 µM NBD-cholesterol (2.5 µl from 2 mM stock) and Lyso PtdCho 
ranging from 0 to 500 µM (0, 2.5, 5, 12.5 and 25 µl from 20 mM stock).  
Fluorescence intensity was determined in the clear filtrate. Fluorescence intensity 
of the aqueous solution containing only cholesterol and fluorescent cholesterol, 
and no Lyso PtdCho was at the background level and increased in the filtrates 
containing increasing amounts of Lyso PtdCho (Fig. 7a).  
To determine if cholesterol could reduce the solubility of NBD-cholesterol in 
PBS in a concentration-dependent manner, increasing concentrations of 
cholesterol ranging from 3- 24 µM (0.6, 1.2, 3.6 and 4.8 µl from 5 mM stock) were 
taken in four glass tubes. Equimolar concentration of Lyso PtdCho ranging from 3- 
24 µM (0.15, 0.3, 0.9 and 1.2 µl from 20 mM stock) was added to the cholesterol 
and a constant concentration of 5 µM NBD-cholesterol was taken. Mixed micelles 
in 1 ml of PBS were made as described above. The fluorescence intensity of the 
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aqueous solution gradually decreased as the concentration of unlabeled 
cholesterol used to make mixed micelles increased (Fig. 7b). 
Accumulation of Fluorescent Cholesterol in Macrophages: 
RAW 264.7 macrophages were incubated with mixed micelles containing 
increasing concentrations (0-10 µM) of NBD-cholesterol for 18 hours. Then the 
cells were washed with PBS twice and visualized under fluorescence microscope 
(Fig. 7c). Macrophages showed concentration- dependent increased accumulation 
of NBD-cholesterol in the cytoplasm, which was further confirmed by measuring 
the fluorescence intensity in the corresponding cell lysates (Fig. 7d). Fluorescence 
intensity in cells incubated with 0.25, 0.5,1, 5 and 10 µM of NBD-cholesterol were 
observed to be several folds higher than the background level. 
Mixed Micelles Mediated Cholesterol Uptake is a Quick Process:  
RAW 264.7 macrophages were incubated with cholesterol (unlabeled and 
NBD-cholesterol) / Lyso PtdCho mixed micelles for 0, 2, 4, 6, 12, 18, 24 and 48 
hours. Cells for each treatment condition were incubated with 90 µM cholesterol, 
300 nM NBD-cholesterol and 90 µM Lyso PtdCho (15 µl of mixed micelles/ 500 µl 
of medium). At the end of each time point cells were observed under microscope 
(data not shown) and were lysed to quantify fluorescence intensity in the cell 
lysates. It was observed that within two hours the fluorescence intensity of the cells 
treated with mixed micelles increased significantly from the background level. 
Furthermore, fluorescence intensity in cell lysates after treatment for 4 hours 
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increased slightly from 2 hours and almost reached a plateau between 4 to 18 
hours. However, after a steady increase in fluorescence intensity at 24 hours, there 
was a sharp decrease in fluorescence intensity level at the 48 hour time point even 
though it was still several fold higher than the background level (Fig. 7e). 
Mixed Micelles of Cholesterol in Aqueous Solution are Stable: 
Mixed micelles of cholesterol, NBD-cholesterol and Lyso PtdCho in PBS 
was prepared as described before and aliquots of the filtrate were stored at room 
temperature, at 4°C and -20°C. Fluorescence intensity of the filtrate from each 
storing condition was determined at week 0, week 1, week 2 and week 4 from the 
storage time. Mixed micelle solution from each temperature was filtered again right 
before their use to measure fluorescence intensity or to treat the cells. We 
observed that the fluorescence intensity of the solution stored at room temperature 
started deteriorating rapidly, while the fluorescence intensity of the solutions stored 
at 4°C and -20°C were fairly stable up to four weeks (Fig 8a). Furthermore, the 
mixed micelles stored at -20°C for four weeks were used to develop macrophage 
foam cells (Fig. 8b). Fluorescent cholesterol accumulation in the macrophages was 
documented by taking images under fluorescence microscope and droplets of CE 
were identified by Oil Red O staining. 
Fluorescent cholesterol accumulation was further quantified by measuring 
fluorescence intensity in the cell lysates (Fig. 8c) and the accumulated CE droplets 
were quantified by eluting the Oil red O stain (Fig. 8d). Measurement of 
fluorescence intensity and elution of Oil red O stain both confirmed the previous 
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observations regarding the stability of mixed micelles at different temperatures. 
Cells treated with micelles stored at 4°C and -20°C showed almost no change in 
NBD-cholesterol or CE droplet accumulation from the starting time point (week 0). 
However, there was a sharp decrease in the accumulation of NBD-cholesterol and 
CE droplets in cells treated with micelles stored at room temperature. 
In order to substantiate the observations regarding the stability of mixed 
micelles additional experiments were performed. Mixed micelles were prepared 
using cholesterol (unlabeled and 3H-cholesterol) and Lyso PtdCho and filtered 
micelles were stored as described in the previous section. Measurements of 
radioactivity in the micelles stored at room temperature, 4°C and -20°C were done 
at week 0, week 1, week 2 and week 4. Micelles stored under these conditions 
were further used to incubate RAW 264.7 macrophages for 18 hours. Each time 
before using, the micelles stored at different temperatures were filtered through 
0.22 µm filter. Stability of the 3H-cholesterol containing micelles (Fig. 8e) mimicked 
the results of micelles containing NBD-cholesterol. More interestingly, cells treated 
with 40 µl (per ml of medium) of 3H-cholesterol containing micelles stored at room 
temperature showed steadily decreasing incorporation of cholesterol in total 
extracted lipid (Fig. 8g) as well as in CE fraction (Fig. 8f). Incorporation of 
cholesterol in total extracted lipid (Fig. 8g) and in CE fraction (Fig. 8f) remained 
almost the same as that of the freshly prepared micelles when cells were treated 
with micelles stored at 4°C and -20°C even after four weeks (TLC plate- Fig. 15). 
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Mixed Micelles Mediated Cholesterol Uptake does not Cause Cell Cytotoxicity: 
Amount of lactate dehydrogenase secreted into the medium during the 
incubation of cells with cholesterol (or CE) / Lyso PtdCho mixed micelles was 
measured to rule out the cytotoxic effect of the mixed micelles (Fig. 9a). Mixed 
micelles contained 3 mM Lyso PtdCho alone, 3 mM cholesterol or CE with 
equimolar Lyso PtdCho. Macrophages were seeded in 96-well plate in 1 X 105/well 
concentration and after 24 hours were washed with PBS twice and incubated with 
120 µl of RPMI containing 0.1% LPDS for 4 hours. Cell were then incubated with 
1 µg Ac-LDL per well (bar 2), 50 (2 µl from 3 mM Lyso PtdCho containing mixed 
micelles) and 75 µM (3 µl) Lyso PtdCho micelles per well (bar 3-4), 50 (2 µl from 
3 mM cholesterol/ Lyso PtdCho containing mixed micelles) and 75 µM (3 µl) 
cholesterol/ Lyso PtdCho mixed micelles per well (bar 5-6) and 25 (1 µl from 3 mM 
CE/ Lyso PtdCho containing mixed micelles) and 50 µM (2 µl) CE/ Lyso PtdCho 
mixed micelles per well (bar 7- 8) for 18 hours. All the treatments were done in 
triplicates and at the end of 18 hours 100 µl medium was collected from each well 
to measure LDH activity in the sample. In this colorimetric assay pink colored 
formazan was measured. Cells incubated with Lyso PtdCho micelles produced 
very dark-pink color indicating very high cell lysis; whereas cells treated with 
cholesterol or CE/ Lyso PtdCho mixed micelles produced very pale pink color as 
was observed in the cells without any treatment. Thus, cells treated with 
cholesterol or CE / Lyso PtdCho mixed micelles were devoid of toxicity.  
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Cytotoxic Effects of Lyso PtdCho are Greatly Reduced by the Presence of 
Cholesterol in Mixed Micelles: 
RBC diluted in saline were mixed with Lyso PtdCho micelles or cholesterol/ 
Lyso PtdCho or CE/ Lyso PtdCho mixed micelles containing 0, 10, 25, 50, 100, 
150, 200 and 250 µM of Lyso PtdCho or cholesterol or CE. Cholesterol and CE 
contain mixed micelles also had equimolar concentrations of Lyso PtdCho. The 
reaction mixture containing Lyso PtdCho micelles showed almost immediate 
hemolysis and optical density value of the supernatant of the reaction mixtures 
were several folds higher when compared with background. Conversely, reaction 
mixture containing cholesterol/ Lyso PtdCho mixed micelles showed almost no 
hemolysis even at the end of 15 minutes incubation and optical density value of 
the supernatant of the reaction mixtures was barely above the background level. 
Nevertheless, the hemolytic properties of CE/ Lyso PtdCho mixed micelles were 
in between the other two micelles. At lower concentrations, between 10- 100 µM 
CE/ Lyso PtdCho did not cause very significant amount of hemolysis, even though 
the amount of hemolysis was higher than that induced by cholesterol/ Lyso PtdCho 
mixed micelles. There was a sharp increase in the level of hemolysis in the reaction 
mixtures containing more than 100 µM CE/ Lyso PtdCho mixed micelles. Between 
150- 250 µM concentrations, levels of hemolysis caused by CE/ Lyso PtdCho 
mixed micelles were almost the same as those of Lyso PtdCho micelles (Fig. 9b).  
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Lyso PtdCho Component of Mixed Micelles was metabolized into PtdCho: 
Cells treated with cholesterol/ Lyso PtdCho (unlabeled and 14C-Lyso 
PtdCho) mixed micelles for 18 hours demonstrated that more than 75% of Lyso 
PtdCho, provided as the component of mixed micelles was metabolized into 
PtdCho (Fig. 9c). The metabolization of Lyso PtdCho to PtdCho was a very quick 
process, which took place within 2 hours (data not shown) as demonstrated 
previously (121, 122).   
Foam Cells are developed by Incubating Macrophages with Cholesterol 
Containing Mixed Micelles: 
RAW 264.7 macrophages and mouse peritoneal macrophages were 
incubated with mixed micelles for 18h. 40 µl of mixed micelles which was used per 
ml of medium, contained 120 µM cholesterol (unlabeled), 400 nM NBD-cholesterol 
and 120 µM Lyso PtdCho (panel iii and vi), while mixed micelles containing CE (24 
µl of CE mixed micelles/ ml of medium) had 72 µM unlabeled CE, 240 nM 
fluorescently labeled CE and 72 µM Lyso PtdCho (panel iv and vii) (Fig. 10a). Ac-
LDL (10 µg/ml, panel ii) treated macrophages were used as positive control for all 
the foam cell development studies. Macrophages incubated with cholesterol / Lyso 
PtdCho micelles were provided with 40 µM oleic acid to aid CE conversion and 
accumulation. When observed under the fluorescence microscope, cells treated 
with NBD-cholesterol containing mixed micelles showed fluorescent cholesterol 
accumulation within the cells. As expected negative control cells (panel i and v) 
and cells treated with Ac-LDL (panel ii) did not yield any fluorescent images. To 
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ensure the accumulation of fluorescent cholesterol was only within the cells, we 
lysed RAW 264.7 macrophages and measured the fluorescence intensity in the 
cell lysate. Fluorescence intensity in the cell lysates of negative control was 
comparable to that of the background level whereas fluorescence intensity was 
much higher in the lysate of cells incubated with mixed micelles (data not shown). 
CE droplet accumulation in RAW 264.7 macrophages was demonstrated by 
Oil red O staining following the treatment with Ac-LDL, cholesterol/ Lyso PtdCho 
and CE/ Lyso PtdCho mixed micelles. Oil red O stain was eluted after the images 
were taken. Eluted Oil red O stain which indirectly quantifies the amount of CE 
droplets present in the cells was taken in 100 µl aliquots and absorption was 
measured at 500 nm. Optical density value of all the three samples matched very 
closely and ranged between 0.3-0.4 (Fig. 10b).    
Quantity of CE Accumulated in Foam Cells Developed by Ac-LDL Mediated 
Uptake or Mixed Micelles Mediated Uptake are Similar: 
RAW 264.7 macrophages were treated with 10 µg/ml of Ac-LDL labeled 
with 3H-cholesterol or with cholesterol (unlabeled and 3H-cholesterol) / Lyso 
PtdCho mixed micelles for 18 hours. Quantification of cholesterol incorporation in 
total extracted lipid showed, foam cells developed by Ac-LDL mediated and mixed 
micelles mediated uptake contained 22 nmoles and 26 nmoles of cholesterol 
(volume of total extracted lipid was 50 µl) respectively (Fig. 10c).  Cholesterol 
incorporation in the CE fraction of extracted lipid was 1.5 nmoles for Ac-LDL 
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mediated foam cell development and 1.8 nmoles for that of mixed micelles (Fig. 
10d).  
Cholesterol is esterified into CE during Micelle Mediated Foam Cell Formation: 
RAW 264.7 macrophages incubated with cholesterol / Lyso PtdCho mixed 
micelles were simultaneously treated with 14C- Oleic acid to study the incorporation 
of radioactive oleate during the esterification of cholesterol into CE. 40 µM oleic 
acid (with 200 pCi radioactivity) / ml of medium was supplied during the incubation 
of cells with cholesterol or CE / Lyso PtdCho mixed micelles and after overnight 
incubation lipids were extracted using methanol / chloroform (2:1). TLC separation 
of the samples from both types of micelle treatments showed distinct spots of CE 
when compared with the standard CE spot and these spots were further analyzed 
for radioactivity.  Before exposing the TLC plate to iodine vapor, radioautograph 
image of the TLC plate was taken and image clearly demonstrated much higher 
oleate incorporation in cells incubated with cholesterol / Lyso PtdCho micelles (Fig. 
10e-insert). This observation was further confirmed when analysis for oleate 
incorporation in CE showed that cells incubated with CE / Lyso PtdCho micelles 
had a 10-fold percentage decrease in 14C- Oleic acid incorporation in CE compared 
to cells treated with cholesterol / Lyso PtdCho micelles (Fig. 10e).  
The Uptake of Cholesterol Micelles is Distinct from that of Ac- LDL: 
Fucoidan and Polyinosinic acid are ligands for SR-A1 and they reduce or 
inhibit the uptake of Ac-LDL by macrophages (123, 124). However, fucoidan or 
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polyinosinic acid did not inhibit the accumulation of fluorescent cholesterol or CE 
in RAW 264.7 macrophages (Fig. 11a- b). 50 µg/ml of fucoidan and 100 µg/ml of 
polyinosinic acid were used separately to block Ac-LDL mediated foam cell 
formation. Oil Red O staining demonstrated that macrophages pre-incubated with 
fucoidan or polyinosinic acid accumulated very little to no CE droplets when treated 
with Ac-LDL. But under the same conditions, macrophages incubated with 
cholesterol (or CE) / Lyso PtdCho mixed micelles accumulated plenty of CE 
droplets (Fig. 11c). 
Quantification of CE droplet accumulation by Oil red O stain elution further 
established this observation. While the optical density of stains eluted from cells 
treated with Ac-LDL following the pre-incubation with fucoidan or polyinosinic acid 
decreased by 2-folds from the positive control, the same pre-incubation had little 
or no effects on the CE droplet accumulation in cells treated with cholesterol or 
CE/ Lyso PtdCho mixed micelles (Fig. 11d).  
The unique nature of foam cell development by mixed micelles was further 
established by using 3H-cholesterol labeled Ac-LDL and mixed micelles. Pre-
treatment of fucoidan and polyinosinic acid decreased the incorporation of 
cholesterol both in total extracted lipid and in  a CE fraction by 4-folds and 2-folds 
respectively in case of Ac-LDL mediated foam cell development. Fucoidan and 
polyinosinic acid did not have any effect on the incorporation of cholesterol in total 
extracted lipid and in CE fraction (Fig. 17) when foam cell development was 
mediated by cholesterol (unlabeled and 3H-cholesterol)/ Lyso PtdCho mixed 
micelles (Fig. 11a- b). 
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HDL Causes Cholesterol Efflux from Foam Cells: 
Foam cells were developed by incubating RAW 264.7 macrophages and 
mouse peritoneal macrophages with cholesterol (unlabeled and NBD-cholesterol 
or 3H cholesterol)/ Lyso PtdCho mixed micelles and used for the efflux study in 
presence of HDL. Foam cells were incubated with 0, 25, 50, 100 and 200 µg/ml of 
freshly prepared HDL. After 4 hours medium was collected from each well and 
RAW 264.7 macrophages were lysed to measure the presence of NBD-cholesterol 
in the medium and in the cell lysates respectively. Fluorescence intensity in the 
medium collected from foam cells alone (no HDL) was in the background level and 
increased in a HDL-concentration dependent manner (Fig. 13a). A similar 
observation was made with respect to cholesterol efflux when mouse peritoneal 
macrophages were used (Fig 13a- insert). Inversely the fluorescence intensity in 
the lysate of foam cells without HDL incubation was the maximum. Fluorescence 
intensity in the lysate of foam cells decreased gradually as the concentration of 
HDL in the medium increased (Fig. 13b). Images were taken under fluorescence 
microscope after the incubation of foam cells with or without HDL. Reduction in 
fluorescence intensity indicated less amount of NBD-cholesterol remained inside 
the foam cells when incubated with increasing concentrations of HDL. Study of CE 
droplet accumulation by Oil red O staining further confirmed our observations (Fig. 
13c). 
These results were further validated in the efflux study using 3H- cholesterol. 
CPM value for 3H- cholesterol efflux was converted into nmoles and presented 
(Fig. 14a). Further analysis showed that 25- 200 µg of native HDL caused 
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cholesterol efflux ranging between 10- 25% of cholesterol present in total extracted 
lipid (Fig. 14b). Preliminary results indicated that most of the cholesterol in the 
medium was associated with intact, reisolated HDL (data not shown). 
HDL Mediated Cholesterol Efflux is Quantitatively Similar from Foam Cells 
Developed by Ac-LDL and Mixed Micelles: 
Foam cells developed by 3H-cholesterol labeled Ac-LDL and cholesterol 
(unlabeled and 3H- cholesterol) / Lyso PtdCho mixed micelles were incubated with 
0, 25 and 50 µg of native HDL for 4 hours. Quantitatively the cholesterol efflux by 
25 and 50 µg of HDL from foam cells developed by mixed micelles were a little bit 
higher than that from Ac-LDL derived foam cells (Fig. 14c). However, when the 
percentage of cholesterol efflux was calculated with respect to cholesterol present 
in total extracted lipid, the efflux rate was very similar. Incubation with 25 and 50 
µg of HDL caused 2- fold and 3- fold induction in cholesterol efflux from foam cells 
developed from either method of cholesterol loading (Fig. 14d).  
Ox-HDL Fails to Cause Cholesterol Efflux: 
Cholesterol efflux from foam cells were compared in presence of 25 µg and 
50 µg native HDL and MPO and Cu mediated Ox-HDL. Cholesterol efflux was 
documented by measuring the fluorescence intensity in medium after incubation 
of foam cells with 25 µg and 50 µg native HDL and Ox-HDL. Even though Cu Ox-
HDL caused some cholesterol efflux, 25 µg and 50 µg native HDL induced much 
higher cholesterol efflux when compared to that of Ox-HDL counterparts (Fig. 13d). 
As seen in the figure MPO mediated oxidation of HDL was more effective at 
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inhibiting cholesterol efflux than copper mediated oxidation. Cholesterol efflux in 
presence of Ox-HDL was further confirmed by using NBD-cholesterol loaded 
mouse peritoneal macrophages (Fig. 13e) and 3H- cholesterol loaded foam cells 
(data not shown). 
Discussion: 
In this study, we demonstrated for the first time that macrophage foam cells 
can be developed using micellerized cholesterol or CE. The foremost challenge to 
incorporate cholesterol in cells is obviously its high hydrophobicity. The amphiphilic 
property of Lyso PtdCho, which is also a natural detergent, was utilized to form 
mixed micelles and to solubilize cholesterol and CE (unlabeled and fluorescently 
labeled) in PBS. A previous study has demonstrated that Lyso PtdCho could form 
stable, soluble complex with equimolar cholesterol (125) and this technique has 
been modified successfully to solubilize β-carotene in aqueous solution (105). 
Augé et al (105) further demonstrated that solubilized β-carotene could be utilized 
for cellular enrichment of β-carotene in vitro. In the present study, increasing 
amounts of cholesterol (unlabeled and NBD-cholesterol) were successfully 
solubilized in PBS by gradually raising the concentration of Lyso PtdCho in the 
mixed micelles. Solubility of NBD-cholesterol was demonstrated directly by 
measuring the fluorescence intensity of the aqueous solution. We validated the 
solubility of cholesterol in aqueous solution indirectly by reducing the solubility of 
NBD-cholesterol in a cholesterol concentration-dependent manner. As the 
concentration of cholesterol provided to make mixed micelles was gradually 
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increased, while keeping the concentration of NBD-cholesterol constant, the 
fluorescence intensity of the aqueous solution was decreased in a concentration 
dependent manner. RAW 264.7 macrophages were loaded with NBD-cholesterol 
and unlabeled cholesterol in a concentration-dependent manner and fluorescently 
labeled cholesterol enriched foam cells were developed. Foam cells were 
successfully generated by using mouse peritoneal macrophages as well. We also 
observed that mixed micelle mediated NBD-cholesterol uptake is a very rapid 
process and cells were enriched with NBD-cholesterol as quickly as within 2 hours 
continuing up to 24 hours. Nonetheless, there was a sharp decline in the 
fluorescence intensity level at 48 hours which was due to detachment of many cells 
as a result of over-confluence. 
It would be worth noting that previous studies demonstrated that NBD-
cholesterol has a higher aqueous solubility than cholesterol and might not truly 
represent the uptake and efflux of cholesterol (37). Higher solubility of NBD-
cholesterol has been utilized for uptake studies by directly incubating cells with 
NBD-cholesterol in ethanol solution (37, 104). The influence of higher solubility of 
NBD-cholesterol in the results of cholesterol uptake and efflux studies was ruled 
out by using 3H-cholesterol, a more widely used cholesterol analog to repeat the 
key experiments. Recently, Khera et al (78) and Li et al (81) utilized macrophages 
labeled with free radioactive cholesterol for high-throughput cholesterol efflux 
study. The enrichment of macrophages with free 3H-cholesterol or 14C-cholesterol 
was done by incubating cells with free radioactive cholesterol for 24 hours. 
However, the goal of our present study was to develop foam cells enriched with 
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cholesterol and CE, not just with fluorescent or radiolabeled cholesterol, by a 
novel, reproducible and quick technique. Therefore, Lyso PtdCho micelle mediated 
cholesterol delivery was a more suitable approach to solubilize and to ensure the 
delivery of highly hydrophobic cholesterol and CE to the cells. Besides, we 
documented that the free cholesterol delivered by micelles gets esterified to CE 
and produces CE droplet enriched foam cells. It is also to be noted that cellular 
cholesterol efflux is also accompanied by cellular phospholipid efflux. As noted in 
our studies, Lyso PtdCho is efficiently converted to PtdCho and thus would provide 
the PtdCho needed for efficient efflux. It remains to be established whether the 
fluorescence/ radioactivity of both cholesterol and PtdCho are associated with HDL 
fraction in the medium.  Our preliminary results (data not shown) suggests that 
most of the fluorescence in the medium is associated with isolated HDL after 
incubation with foam cells containing NBD-cholesterol.   
Incorporation of 14C oleate was studied to ascertain that esterification of 
cholesterol into CE is indeed the source of lipid droplets seen inside the foam cells 
upon incubation with cholesterol / Lyso PtdCho micelles. Cells incubated with 
cholesterol / Lyso PtdCho micelles yielded the CE band comparable to one from 
CE / Lyso PtdCho micelle treated cells, upon TLC separation (Fig. 16). 
Nonetheless, cholesterol / Lyso PtdCho micelle treated cells showed very high 14C 
oleic acid incorporation, while CE / Lyso PtdCho micelle treated cells had a 10-fold 
reduction in oleate incorporation. This demonstrated that cholesterol / Lyso PtdCho 
mixed micelles generated foam cells, which would be physiologically relevant as 
cholesterol was esterified into CE and appeared as lipid droplets during Oil red O 
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staining. For all the experiments involving cholesterol (unlabeled and NBD or 3H-
cholesterol) / Lyso PtdCho micelles, cells were incubated with 40 µM oleic acid 
along with the micelles. Oleic acid was supplied to facilitate the esterification of 
cholesterol into CE and has been used in many studies to follow Ac- LDL uptake.    
Lyso PtdCho is known to induce cell lysis due to its detergent like properties 
and causes cell lysis by breaking down the intact cell membrane (125-127). It was 
observed in the current study that Lyso PtdCho alone is highly soluble in PBS and 
caused massive cell death. Cell lysis was confirmed by measuring secretion of 
LDH in medium upon incubation of cells with Lyso PtdCho micelles. However, cell 
morphology was not affected by the incubation with cholesterol/ Lyso PtdCho 
mixed micelles, as clearly demonstrated in Fig. 10a (panel iii). We also 
demonstrated that red blood cells were resistant to lysis when increasing 
concentrations of cholesterol were present along with Lyso PtdCho. This 
observation was not surprising as the work of Rand et al (125) explained that stable 
complex between equimolar cholesterol and Lyso PtdCho causes a 
conformational change in micelle formation, leading to reduction in the 
destabilizing and lytic effects of Lyso PtdCho. The reduced lytic effects of 
cholesterol/ Lyso PtdCho mixed micelles were clearly established by its reaction 
with RBC. Incubation of RBC with Lyso PtdCho micelles for 15 minutes, lysed RBC 
releases hemoglobin in the aqueous solution, while the same reaction with an 
equivalent amount of cholesterol/ Lyso PtdCho mixed micelles had very little to no 
cell lysis. Nonetheless, CE/ Lyso PtdCho mixed micelles induced more cell lysis 
causing increased secretion of LDH (data not shown) in the medium and 
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hemoglobin in the aqueous solution  when compared with that of cholesterol/ Lyso 
PtdCho. One possible explanation could be that CE does not cause conformational 
changes as cholesterol does during mixed micelle formation and thus CE is less 
effective in reducing the lytic effects of Lyso PtdCho. After this initial observation, 
reduced volume of CE/ Lyso PtdCho mixed micelles was used to enrich 
macrophages with CE. Lytic effects of Lyso PtdCho micelles were clearly in effect 
even with the concentration as low as 10 µM of Lyso PtdCho, while presence of 
CE up to a concentration of 100 µM CE has greatly reduced this lytic effect. 
The advantage of using Lyso PtdCho as a membrane fusion agent to deliver 
cholesterol to cells is two-fold as Lyso PtdCho is metabolized by cells into PtdCho 
(an acylation reaction) and glycerophosphorylcholine (a transesterification 
reaction) (121) as previous studies demonstrated this conversion using various cell 
lines including macrophages (122). The quick metabolism of Lyso PtdCho by cells 
ensures successful cargo delivery to the cells without influencing RCT. We 
observed that more than 75% of Lyso PtdCho, delivered as mixed micelles, was 
metabolized into PtdCho within 2 hours of incubation of cells with cholesterol/ Lyso 
PtdCho (unlabeled and 14C- tagged) mixed micelles. 
We have further established that micellerized CE uptake is uniquely 
distinguished from Ac-LDL uptake. SR-A1 is actively involved in Ac-LDL binding 
and Ac-LDL mediated uptake of cholesterol (123). We have used fucoidan and 
polyinosinic acid, known ligands for SR-A1 (124) to inhibit the binding of Ac-LDL 
to SR-A1. As expected fucoidan and polyinosinic acid prevented the Ac-LDL 
mediated foam cell formation, greatly inhibited the incorporation of 3H-cholesterol 
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in total extracted lipid and in the CE fraction of lipids in Ac-LDL treated cells. 
However, SR-A1 ligands had no effects on cholesterol or CE/ Lyso PtdCho mixed 
micelle mediated cholesterol delivery and the accumulation of NBD-cholesterol 
remained unaffected. Additionally, fucoidan and polyinosinic acid had no inhibitory 
effects in the incorporation of 3H-cholesterol in total extracted lipid and in the CE 
fraction of lipids when macrophages were incubated with cholesterol/ Lyso PtdCho 
mixed micelles. Thus the micelle mediated cholesterol or CE delivery utilizes the 
membrane fusion property of Lyso PtdCho, making this foam cell development 
technique novel and unique. Furthermore, the universality of micelle mediated 
delivery was established by developing cholesterol enriched hepatocyte, HepG2 
cells (data not shown). 
Currently the development of foam cells, used to study RCT, typically 
involves isolation and acetylation of LDL, followed by incorporation of radiolabeled 
cholesterol. Isolation of LDL is a tedious process and LDL is prone to be oxidized 
automatically during the isolation process (90). Isolation and acetylation of LDL 
can vary qualitatively from one preparation to another, resulting in the induction of 
inflammatory responses in animal models. Most importantly, Ac-LDL preparations 
are not stable and cannot be stored for a long time. In our present study we have 
established that cholesterol or CE/ Lyso PtdCho mixed micelle preparation is 
functionally stable at 4°C and -20°C up to one month while mixed micelle 
preparation stored at -20°C is stable for even longer time (data not shown). 
Furthermore, mixed micelle preparation stored at -20°C for one month was used 
to develop macrophage foam cells, which were qualitatively similar to those 
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developed with freshly prepared mixed micelles. Quantitative analysis of foam cells 
developed with mixed micelles stored at 4°C and -20°C up to one month revealed 
storage time did not affect the accumulation of NBD-cholesterol, CE droplets or 
incorporation of 3H-cholesterol in total extracted lipid and in the CE fraction of the 
lipid. Extraction of lipids from the mixed micelle preparation stored at 4°C and -
20°C for several weeks followed by analysis from TLC separation showed no 
decrease in Lyso PtdCho and cholesterol content (data not shown).  
We also observed that mixed micelle mediated cholesterol loading was 
highly reproducible and the amount of cholesterol incorporated in the total 
extracted lipid always ranged between 25-27 nmoles when cells were incubated 
with cholesterol (unlabeled and 3H-cholesterol) / Lyso PtdCho mixed micelles (data 
not shown). The same treatment resulted in the incorporation of 1.5- 1.8 nmoles 
of cholesterol in CE fraction of the lipid when the experiment was repeated five 
times or more (data not shown).  
Foam cells developed by using cholesterol/ Lyso PtdCho mixed micelles 
were efficiently used to study cholesterol efflux. Increased concentration of HDL 
caused a concentration-dependent cholesterol efflux from the foam cells and was 
quantified by measuring the amount of NBD-cholesterol in the medium. For the 
efflux study, foam cells were also developed using cholesterol (unlabeled and 3H-
cholesterol) / Lyso PtdCho mixed micelles and concentration-dependent efflux of 
3H-cholesterol confirmed our observation to that of NBD-cholesterol efflux. It 
should also be noted that HDL- mediated cholesterol efflux from foam cells 
developed by mixed micelles were quantitatively very similar from foam cells 
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developed by Ac-LDL. Various studies have suggested that oxidation of HDL leads 
to the loss of its anti-atherogenic property. To determine if the micelle derived foam 
cells could be utilized to differentiate between native, functional HDL and oxidized, 
dysfunctional HDL, we used equal concentrations of native and Ox-HDL 
separately. As we expected Ox-HDL failed to induce any significant cholesterol 
efflux from the foam cells. Therefore, we conclude that the foam cells developed 
by using cholesterol/ Lyso PtdCho mixed micelles can be potentially used to study 
RCT in subjects with or without the background of cardiovascular diseases. 
Development of foam cells loaded with fluorescently labeled cholesterol via 
mixed micelles mediated technique would be less time consuming and highly 
reproducible. Furthermore, these foam cells could be utilized to screen a large 
number of human plasma/HDL samples to determine the efficacy of cholesterol 









Figure 7. Solubilization of NBD-cholesterol/ Lyso PtdCho Micelles. 
Cholesterol (unlabeled) and NBD-cholesterol were mixed together and solubilized in presence of 
Lyso PtdCho to form mixed micelles, a) solubilization of cholesterol and NBD-cholesterol in 
presence of increasing concentrations of Lyso PtdCho; b) solubilization of NBD- cholesterol is 
inhibited by cholesterol in a concentration-dependent manner; c) concentration-dependent 
increased uptake of fluorescent cholesterol by RAW 264.7 macrophages, cells were treated with 
mixed micelles containing 0- 10 µM NBD-cholesterol, after 18 hrs cells were visualized under 
fluorescence microscope (40X objectives); d) cells treated as above were lysed using methanol 
and fluorescence intensity was measured using fluorescence plate reader; e) cells were treated 
with cholesterol, NBD-cholesterol/ Lyso PtdCho mixed micelles for 0- 48 hrs and fluorescence 
intensity in the cell lysate were measured. Values are expressed as mean ± SD (n ≥ 3). ** P < 0.01, 





Figure 8. Stability of NBD-cholesterol/ Lyso PtdCho Micelles. 
a) Cholesterol, NBD-cholesterol/ Lyso PtdCho mixed micelles were stored at room temperature, 
4°C and -20°C for week 0- week 4 and fluorescence intensity of the micellerized NBD-cholesterol 
solution stored at different temperatures up to 4 weeks was measured; b) foam cells containing 
NBD-cholesterol was developed by incubating macrophages with mixed micelles stored at -20°C 
for four weeks; c) cells were treated with fluorescently labeled mixed micelles stored at room 
temperature, 4°C and -20°C for week 0- week 4 and fluorescence intensity in the cell lysates were 
measured; d) absorbance value of Oil red O stain eluted after staining the cells as treated above; 
e) cholesterol, 3H-cholesterol/ Lyso PtdCho mixed micelles were stored at room temperature, 4°C 
and -20°C for week 0- week 4 and radioactivity of the micellerized cholesterol solution stored at 
different temperature up to 4 weeks was measured (count per minute values were converted into 
nmoles of cholesterol and represented); f) cells were treated with 3H-cholesterol labeled mixed 
micelles stored at room temperature, 4°C and -20°C for week 0- week 4 and incorporation of 
cholesterol in CE fraction were measured; g) incorporation of cholesterol in the total extracted lipid 
after the treatment of cells was measured as mentioned above. Values are expressed as mean ± 
SD (n ≥ 3). * P < 0.05, ** P < 0.01, *** P < 0.005 (one-way ANOVA with Dunnett’s multiple 
comparison test). Significant differences in values for different storage temperatures and time-






Figure 9. Foam Cells Were Developed Using Cholesterol or CE (Unlabeled) 
/Lyso PtdCho Mixed Micelles Without Inducing Cytotoxic Effects. 
a) Lactate dehydrogenase secreted in the medium was used to quantify LDH activity  (µU/ml) in 
samples treated under different conditions- no treatment, 1 µg Ac-LDL, 50 and 75 µM Lyso PtdCho 
micelles or cholesterol/ Lyso PtdCho micelles, 25 and 50 µM CE/ Lyso PtdCho micelles per well. 
P values for samples treated with Lyso PtdCho alone were calculated against control (no 
treatment), for samples treated with cholesterol or CE /Lyso PtdCho mixed micelles were calculated 
against the samples treated with Lyso PtdCho alone. Values are expressed as mean ± SD (n ≥ 3). 
*** or ### P < 0.005 (one-way ANOVA with Bonferroni’s multiple comparison test). b) Hemolysis of 
human RBC was demonstrated by adding increasing concentrations of Lyso PtdCho micelles, 
cholesterol/ Lyso PtdCho or CE/ Lyso PtdCho mixed micelles to constant concentration of RBC 
and optical density of the reaction mixture was measured; c) metabolization of 14C- Lyso PtdCho 
used as the component of cholesterol/ Lyso PtdCho micelles was demonstrated. Values are 






Figure 10. Foam Cells Developed Using Mixed Micelles Show Cholesterol 
Esterification. 
a) RAW 264.7 (panel i- iv) and mouse peritoneal macrophages (panel v-vii) incubated with mixed 
micelles for 18 hours showed accumulation of NBD-cholesterol (iii- RAW 264.7 macrophages and 
vi- mouse peritoneal macrophages) and fluorescent CE (iv- RAW 264.7 macrophages and vii- 
mouse peritoneal macrophages) droplet under fluorescence microscope. CE droplet accumulation 
demonstrated by Oil Red O staining. CE droplet accumulation was observed in cells treated with 
Ac-LDL (ii- RAW 264.7 macrophages), cholesterol (iii- RAW 264.7 macrophages and vi- mouse 
peritoneal macrophages) or CE (iv- RAW 264.7 macrophages and vii- mouse peritoneal 
macrophages)/ Lyso PtdCho mixed micelles; b) Oil red O stain from RAW 264.7 macrophages 
treated with Ac-LDL and cholesterol/ Lyso PtdCho or CE/ Lyso PtdCho mixed micelles were eluted 
and absorbance was measured; c) cells were treated with 3H-cholesterol labeled Ac-LDL or 
cholesterol, 3H-cholesterol/ Lyso PtdCho mixed micelles and incorporation of cholesterol in total 
extracted lipid was measured; d) incorporation of cholesterol in CE fraction was measured following 
the above mentioned treatment; e) cells incubated with cholesterol or CE / Lyso PtdCho mixed 
micelles were supplied with 40 µM 14C-oleic acid / ml. Cells incubated with CE / Lyso PtdCho 
mixed micelles showed almost 10-fold less 14C-oleic acid incorporation than those treated with 
cholesterol / Lyso PtdCho mixed micelles. Insert shows radioautography image of 14C-oleic acid 
incorporation in CE fraction of cells as treated above. Values are expressed as mean ± SD (n ≥ 3). 






Figure 11. Mixed Micelle Mediated Foam Cell Formation is not affected by 
Scavenger Receptor Binding Ligands. 
a) Macrophages were pre-incubated with either 50 µg/ ml fucoidan or 100 µg/ ml polyinosinic acid, 
followed by incubation with cholesterol or CE (unlabeled and fluorescently labeled)/ Lyso PtdCho 
mixed micelles for 18 hours. NBD-cholesterol or fluorescent CE accumulation within macrophages 
was observed in the cells pre-incubated with fucoidan and polyinosinic acid; b) measurement of 
fluorescence intensity in cell lysates from cells treated with fluorescently labeled cholesterol or CE 
with or without fucoidan or polyinosinic acid treatment; c) Macrophages pre-incubated with fucoidan 
and polyinosinic acid showed very little to no CE droplet accumulation after treatment with Ac-LDL 
(i). CE droplet accumulation in macrophages pre-incubated with fucoidan and polyinosinic acid was 
observed after incubation with cholesterol (ii) or CE (iii)/ Lyso PtdCho mixed micelles; d) Oil red O 
stain was eluted from the cells treated with Ac-LDL and cholesterol or CE/ Lyso PtdCho mixed 
micelles with or without the pre-incubation of fucoidan or polyinosinic acid and absorption of Oil red 
O stain at 500 nm was measured. Values are expressed as mean ± SD (n ≥ 3). *** P < 0.005 (one-
way ANOVA with Dunnett’s multiple comparison test). Significant differences for fucoidan and 
polyinosinic treatment are always compared with the respective positive control. 




Figure 12. Incorporation of Cholesterol is not inhibited by Pre- incubation 
with Fucoidan or Polyinosinic Acid. 
a) RAW 264.7 macrophages were treated with 3H-cholesterol labeled Ac-LDL or cholesterol, 3H-
cholesterol/ Lyso PtdCho mixed micelles with or without fucoidan and polyinosinic acid pre-
incubation and incorporation of cholesterol in total extracted lipid was measured; b) incorporation 
of cholesterol in CE fraction was measured from cells as treated above. Values are expressed as 
mean ± SD (n ≥ 3). ** P < 0.01, *** P < 0.005 (one-way ANOVA with Dunnett’s multiple comparison 
test). Significant differences for fucoidan and polyinosinic treatment are always compared with the 






Figure 13. Cholesterol Efflux From Foam Cells in Presence of HDL. 
Foam cells were developed using cholesterol (unlabeled and NBD-cholesterol or 3H-cholesterol)/ 
Lyso PtdCho mixed micelles. Foam cells were incubated with 0- 200 µg/ml of HDL for 4 hours. a) 
Medium from NBD-cholesterol containing foam cells (RAW 264.7 macrophages) incubated with 
increasing concentrations of HDL showed concentration-dependent increase in fluorescence 
intensity. Insert shows mouse peritoneal macrophage derived foam cells incubated with HDL 
demonstrating concentration-dependent NBD-cholesterol efflux in the medium; b) fluorescence 
intensity in the corresponding cell lysates decreased as the concentration of HDL increased. * P < 
0.05; ** P < 0.01, *** P < 0.005 (one-way ANOVA with Dunnett’s multiple comparison test). c) 
Fluorescence images and Oil Red O staining showed reduction in CE droplet accumulations in 
cells after incubation with HDL; d) foam cells were incubated with 25 and 50 µg/ml of native HDL 
and MPO or Cu mediated Ox-HDL. Cholesterol efflux caused by native HDL was much higher when 
compared with the same concentration of Ox-HDL. Values are expressed as mean ± SD (n ≥ 3). 
*** P < 0.005 (one-way ANOVA with Dunnett’s multiple comparison test). Significant differences for 
Ox-HDL treatments are always compared with the corresponding concentration of native HDL. e) 
Cholesterol efflux from peritoneal macrophage derived foam cells incubated with 25 and 50 µg/ml 
of native HDL and MPO mediated Ox-HDL. Values are expressed as mean ± SD (n ≥ 3). *** P < 






Figure 14. Ac-LDL and Mixed Micelles Mediated Foam Cells Demonstrated 
Similar HDL-dependent Cholesterol Efflux. 
a) Foam cells developed by incubation with 3H-cholesterol containing mixed micelles showed 
concentration-dependent increase in cholesterol efflux when treated with increasing concentrations 
of HDL; b) HDL- mediated cholesterol efflux was represented as % of cholesterol incorporated in 
total extracted lipid;  c) foam cells were developed by incubating macrophages with 3H-cholesterol 
labeled Ac-LDL or 3H-cholesterol containing mixed micelles and HDL- mediated cholesterol efflux 
was studied using 25 and 50 µg/ml of native HDL; d) HDL- mediated cholesterol efflux represented 
as % of cholesterol incorporated in total extracted lipid. Values are expressed as mean ± SD (n ≥ 







Figure 15. Extracted Lipid was separated on TLC Plate and TLC Plate Exposed to Iodine Vapor. 
Cholesterol (unlabeled and 3H-cholesterol)/ Lyso PtdCho mixed micelles stored at room temperature, 4° C and -20° C for Week 0, 
Week 1, Week 2 and Week 4 were used to incubate RAW 264.7 macrophages for 18 hours. Extracted lipid was used to run TLC 
with cholesterol, cholesteryl ester and Lyso PtdCho standards and one of the representative TLC plate was shown here. TLC plate 







Figure 16. Extracted Lipid was separated on TLC Plate and TLC Plate Exposed to Autoradiography 
Imager Followed by Exposure to Iodine Vapor. 
Cholesterol/ Lyso PtdCho and CE/ Lyso PtdCho mixed micelles along with 14C-Oleic acid were used to incubate RAW 264.7 
macrophages for 18 hours. Extracted lipid was used to run TLC with cholesterol, cholesteryl ester, oleic acid and Lyso PtdCho 






Figure 17. Extracted Lipid was separated on TLC Plate and TLC Plate Exposed to Iodine Vapor. 
3H-cholesterol tagged ac-LDL and cholesterol (unlabeled and 3H-cholesterol)/ Lyso PtdCho mixed were used to incubate RAW 
264.7 macrophages with or without fucoidan or polyinosinic acid for 18 hours. Extracted lipid was used to run TLC with cholesterol 
and cholesteryl ester standards. TLC plate was cut into eight sections for each sample and radioactivity measurement was taken 





CHAPTER 3:  
PLASMA FROM HEART FAILURE PATIENTS WITH NORMAL 
EJECTION FRACTION HAVE BETTER HDL FUNCTIONALITY AS 
COMPARED TO SUBJECTS WITH POOR EJECTION FRACTION  
Introduction 
Population studies from the past few decades have clearly demonstrated 
that plasma HDL has an inverse relationship with the progression of cardiovascular 
disease. Some of the atheroprotective functions of HDL are associated with, but 
not limited to, its role in RCT and the prevention of LDL oxidation (101).  
RCT can be considered as the main defense mechanism against 
atherosclerotic plaque development. The mechanism of RCT involves efflux of 
cholesterol from the peripheral tissue and lipid-laden macrophages to extracellular 
cholesterol acceptor HDL, and the transport of cholesterol to liver for recycling or 
disposal via excretion. ABCA1 and ABCG1 are the major transporters involved in 
the efflux of cholesterol from macrophages. ABCA1 mediated lipid transport 
involves lipid-free or lipid-poor form of HDL, which contains mostly apolipoproteins. 
The models for ABCA1 associated lipid transport suggest that binding of ABCA1 
with apoA-I induces efflux of cholesterol from the plasma membrane. However, 
ABCA1 can bind to a wider range of apolipoproteins such as apoA-II, apoA-IV, 
apoE and apoC. Lipidation of apolipoproteins with cholesterol and phospholipids 
produces pre-β migrating HDL particles which continue to be acceptors of 
cholesterol effluxed via ABCA1 (59, 73, 98, 128). ABCG1 mediated cholesterol 
efflux mostly involves mature α-migrating HDL and ABCG1 associated pathway 
accounts for 6-12% of the free cholesterol efflux from the cell membranes (62). 
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Plasma HDL density varies between 1.06- 1.21 g/ml and the population of 
human plasma HDL constitutes a heterogeneous group of particles which can be 
distinguished based on their size, density, electrophoretic mobility, lipid and 
apolipoprotein composition. Mature HDL can be categorized into 2 major 
populations based on the separation done by ultracentrifugation, i) large, spherical 
HDL2 and ii) small, dense, protein-rich HDL3. Several studies investigating the 
characteristics of HDL3 revealed that majority of the apoA-I in the plasma 
associated with HDL3 and this sub-fraction of HDL is also enriched with several 
anti-oxidant enzymes such as PON1, PAF-AH or lipoprotein associated 
phospholipase A2 and LCAT. Thus, HDL3 is believed to play a critical role not only 
in RCT but also in the anti-oxidative functions associated with HDL (49, 129). 
Additionally, HDL, especially HDL3 is also known to act as an anti-apoptotic factor 
and protects macrophages from Ox-LDL induced apoptosis by stimulating 
cholesterol efflux (130). 
Studies from the last two decades strongly suggested that HDL prevents 
the oxidative modification of LDL and Ox-LDL induced cytotoxicity which are the 
crucial events to initiate atherosclerotic plaque development (101). Co-incubation 
with HDL not only decreased the metal ion or cell induced oxidation of LDL, but 
also reduced the uptake of modified LDL by macrophages. HDL acts as a 
scavenger for lipid peroxides along with preventing the formation of lipid peroxides 
(131, 132). Association of HDL with various enzymes is believed to be responsible 
for its anti-oxidative properties. One of the most potent enzymes involved in the 
anti-oxidative activities of HDL is PON1. Serum PON1 is a calcium dependent 
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esterase, synthesized and secreted by the liver. PON1 catalyzes the hydrolysis of 
organophosphates, insecticides, aromatic carboxylic acid esters, carbamates and 
nerve gas and produces less toxic products (133). HDL provides stability to this 
43-KDa enzyme after its secretion from liver. The affinity of apoA-I to PON1 for 
binding is very high and apoA-I is believed to stimulate the lactonase activity of 
PON1. Previous studies indicated that PON1 protects LDL from oxidation and 
stimulates cholesterol efflux from macrophages (134, 135). Protection of LDL from 
oxidation is believed to be mediated by PON1 in 2 separate ways. Firstly, during 
the metal ion or cell induced oxidation, PON1 inhibits the accumulation of lipid 
peroxides and secondly, PON1 eliminates the pre-formed lipid peroxides (136). 
Moreover, PON1 attenuates the uptake of Ox-LDL by macrophages via SR CD36 
(134), prevents macrophage cholesterol biosynthesis and cholesterol 
accumulation (137). Therefore, PON1 can be considered as the major contributory 
factor to the anti-atherogenic properties of HDL. Anti-oxidative activities of HDL 
are also associated with the functions of PAF-AH, LCAT, and several 
apolipoproteins such as apoA-I, apoA-II, apoA-IV, apoE and apoJ (129).  
Modifications of structure and composition of HDL play a crucial role in the 
progression of several pathological conditions and the alterations of HDL are often 
associated with inflammation, oxidative stress, atherosclerosis and hyperlipidemia. 
One of the major modifications that severely affects the proper functioning of HDL 
is alteration apoA-I. During acute inflammation, the secretion of apoA-I from the 
liver is often decreased or apoA-I on HDL is replaced by SAA (47, 138). 
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Previous studies by several groups indicated that the replacement of apoA-
I by SAA significantly impairs the cholesterol efflux capacity of HDL. Although, the 
native HDL present during acute inflammatory response or SAA containing HDL 
seemed to bind to macrophages with a higher affinity, they are less effective to 
induce free cholesterol efflux from the macrophages under these conditions (138-
140). Furthermore, it has been observed that the acute phase HDL or SAA 
containing HDL promote CE uptake by monocytes and macrophages and thus 
enhance the process of foam cell formation (139). Acute phase HDL or SAA 
containing HDL also have reduced capacity to bind to hepatocytes and deliver 
cholesterol for clearance from the body (141). Therefore, during acute 
inflammation or due to replacement of apoA-I by SAA, HDL become pro-
atherogenic as they promote CE influx to peripheral tissues, become less effective 
to induce cholesterol efflux from macrophages and demonstrate reduced 
association with hepatocytes which is essential for the final steps of RCT. ApoA-I 
is also susceptible to oxidation by metal ions in vitro and by MPO enzyme in vivo. 
Recently the oxidation of HDL associated with MPO has received a lot of attention. 
MPO is a neutrophil granulocyte derived peroxidase enzyme that catalyzes the 
formation of hypochlorous acid from chloride ions and nitrogen dioxide radicals by 
using hydrogen peroxide and nitric oxide as oxidizing agents. In vitro studies have 
showed that MPO catalyzes the chlorination and nitration of specific tyrosine 
residues on apoA-I to form chlorotyrosine and nitrotyrosine respectively (142, 143). 
Moreover, plasma HDL isolated from patients with CAD revealed higher 
concentrations of chlorotyrosine and nitrotyrosine per apoA-I than those present in 
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subjects without the history of CAD (144, 145). Oxidation of apoA-I impairs its 
ability to induce free cholesterol efflux from macrophages. Previous studies have 
suggested chlorination of tyrosine residue 192 on apoA-I disables the strong 
association between apoA-I and ABCA1 transporter which is essential for the efflux 
of cholesterol to lipid poor or lipid free apoA-I and nascent HDL (88, 142). 
Additionally, chlorination of apoA-I prevents the activation of LCAT (88) and thus 
oxidation of HDL affects RCT in a 2-fold way. It has also been suggested that 
oxidation of apoA-II impairs the antioxidant properties of HDL (102). 
HF is one of the most common, disabling and costly public health problem 
and is complex in nature. HF is associated with high rate of morbidity and mortality. 
Population studies show that 30-40% of the patients diagnosed with heart failure, 
die within a year while 60-70% of the mortality happens within 5 years. HF happens 
following the gradual and severe muscle weakness/ stiffening in the heart and 
inefficient pumping of the blood. As the muscle weakness progresses, the organs 
and peripheral tissues receive less amount of oxygenated blood and the pressure 
in the heart gradually increases. EF refers to the percent of the total amount of 
blood in the left ventricle, which is pumped out with each heartbeat. A normal 
heart's EF varies between 55-70% and EF below 40% is a strong indicator of HF. 
Our preliminary studies indicated that the peripheral blood (PB) plasma from 
the human HF patients with low EF had high levels of Ox-LDL accumulation when 
compared with the PB plasma from the HF patients with normal EF. The goal of 
this study was to determine if the accumulation of higher amount of Ox-LDL is a 
reflection of the quality of the HDL. The quality and the functionality of HDL was 
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investigated by performing cholesterol efflux assays with foam cells, generated in 
vitro using cholesterol/Lyso PtdCho mixed micelles (28). Additionally, PON1 
arylesterase activity of the plasma samples was assessed to evaluate the 
functionality of the patients’ HDL as an anti-atherogenic lipoprotein. 
Materials and Methods 
Reagents: 
RPMI 1640, FBS, sodium pyruvate, L-glutamine, PS, 1X PBS, NBD-
cholesterol and Hank’s balanced salt solution (HBSS) were bought from Invitrogen 
Life Technologies (Carlsbad, CA). Cholesterol, calcium chloride (CaCl2), 
magnesium chloride (MgCl2), Lyso PtdCho from egg yolk, oleic acid, 0.9% saline 
and p-Nitrophenyl acetate (p-NPA) were purchased from Sigma-Aldrich (St. Louis, 
MO). Acetone, isopropyl alcohol and ethyl alcohol were purchased from VWR 
international (Randor, PA). [1, 2- 3H (N)] cholesterol was bought from American 
Radiolabeled Chemicals (St. Louis, MO). 
Cell Culture: 
RAW 264.7 macrophages were cultured in RPMI 1640 medium containing 
10% FBS, 1% PS, 1% sodium pyruvate and 1% L-glutamine. Cells were seeded 
at 3 X 105/ 250 µl density in the 48-well plate and incubated at 37° C in a 5 % CO2 
incubator to reach 65-70% confluence overnight. For the experiments involving 




Generation of Foam Cells in vitro: 
Foam cells were generated in vitro as described previously (146). Briefly, 
RAW 264.7 macrophages were incubated with cholesterol (unlabeled and NBD or 
3H-cholesterol)/Lyso PtdCho mixed micelles for 18 hours in presence of 40 µM 
oleic acid.  
Human Subjects: 
 Following the Ohio State University School of Medicine Institutional Review 
Board (IRB) approval, blood was collected from 48 patients (consented) 
undergoing routine cardiovascular surgery [coronary artery bypass grafting 
(CABG), valve repair/replacement (AVR, MVR, TVR: aortic, mitral, or tricuspid 
valve replacements) or other open heart surgeries] at The Ohio State University 
Medical Center. Simpson’s bi-plane technique was used to determine left 
ventricular ejection fractions. Two ml of left ventricular blood (LVB) was collected 
by aspirating blood using a 23 gauge needle and 10cc syringe placed through the 
ventricular apex. Simultaneously 5 ml of PB was collected from a peripheral 
venous line. Blood was collected in heparinized tubes and labeled with number 
associated with the study. Plasma was separated immediately after collection by 
centrifugation at 3000 rpm for 20 minutes. Isolated plasma were stored at -80°C 
for further analysis. No patients had clinical evidence of active ischemia at the time 
of blood sampling. 
For the control group, peripheral blood was collected from the subjects 
undergoing overnight fasting. Blood was collected from the left-hand index finger 
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using blood lancet in a heparinized tube and plasma was isolated as described 
previously. 
Exclusion Criteria: 
Subjects who were on antioxidant supplements (vitamin E, C, beta carotene 
and lipoic acid) were excluded from the study. All the patients were optimized with 
medical management prior to surgery and these included the use of β-blockers, 
ACE inhibitors, statins and diuretic therapy. The use of such therapies themselves 
could affect the built-up of Ox-LDL. As per the clinical criteria HF subjects not older 
than 85 years and EF less than or equal to 70% were included for this study. 
For the control group, the subjects were between 30-65 years of age and 
did not have any history of HF or never underwent any routine cardiovascular 
surgery. 
Cholesterol Efflux Study: 
Raw 264.7 macrophages were washed with sterile PBS twice after 
overnight incubation with cholesterol/Lyso PtdCho mixed micelles. Macrophage 
foam cells were incubated with 400 µl of HBSS and 5 µl plasma samples for 4 
hours. At the end of 4 hour incubation, HBSS was collected from each well and 
efflux of labeled cholesterol was measured. HBSS containing no plasma and 
incubated with foam cells (NBD or 3H-cholesterol labeled) was used for 
background value in the cholesterol efflux experiments. 
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The HBSS and plasma samples incubated with foam cells containing 3H-
cholesterol were collected and  efflux of 3H-cholesterol was measured in 100 µl 
aliquots using liquid scintillation and luminescence Counters (MicroBeta2 Plate 
Counter, PerkinElmer, Waltham, MA). For the cholesterol efflux study involving 3H-
cholesterol, CPM value was converted into nmoles of cholesterol and expressed 
as the unit of measurement. When the cholesterol efflux study was performed 
using NBD-cholesterol containing foam cells, HBSS containing plasma samples 
were subjected to de-proteination steps. 
De-proteination of Samples: 
The HBSS and plasma samples used for cholesterol efflux study involving 
NBD-cholesterol was not suitable for direct fluorescence measurement. The high 
concentration of protein present in the plasma samples interferes with the 
fluorescence measurement and samples have to be subjected to de-proteination.. 
For the de-proteination procedure, 400 µl of HBSS with or without the plasma 
samples were collected in glass test tubes at the end of the 4 hour incubation with 
foam cells. 1 ml of ice-cold acetone and isopropyl alcohol (vol: vol, 1:1) was added 
to HBSS with or without the plasma samples. The solution mixture was incubated 
at 4°C for 30 minutes and centrifuged at 400 g for 10 minutes. Precipitated protein 
pellet was visible at the bottom of the glass tube. Acetone: isopropyl alcohol phase 
of the supernatant was evaporated under nitrogen gas at 30°C without disturbing 
the protein precipitate. After evaporating the organic solvent phase, 100 µl aliquots 
of the supernatants were taken and fluorescence was measured using 
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fluorescence plate reader (Envision 2014 Multilabel Plate Reader, PerkinElmer, 
Waltham, MA). Fluorescence of effluxed NBD-cholesterol was measured at 
emission spectra of 535 nm upon excitation at 485 nm. 
PON1 Assay: 
The plasma PON1 arylesterase activity was measured by following the 
method of Jaichander et al (147). Briefly, 10 µl aliquots of human plasma was 
incubated with 1 mM p-NPA in 100 µl phosphate buffer with 2 mM CaCl2 and 
MgCl2 at 37°C for 30 minutes. The reaction was set up in 96-well plate and the 
reaction for each patient plasma sample was set up in triplicates. p-NPA was used 
as the substrate for PON1 enzyme activity and the resultant product p-Nitrophenol 
conversion was measured at 410 nm.  
Statistical Analysis: 
Each experiment was performed more than three times and each 
experimental condition was set up in triplicates. All values were presented as mean 
± standard deviation. Analysis of variance (ANOVA) was applied with Bonferroni’s 
correction for multiple comparisons using GraphPad Prism 5.0 software (San 




PB Plasma from Patients with Lower EF Showed Reduced Cholesterol Efflux: 
Foam cells generated with cholesterol/Lyso PtdCho mixed micelles were 
used for cholesterol efflux studies in presence of PB plasma from patients. The 
patient group with EF >60% showed almost 3-fold higher cholesterol efflux than 
the group with EF <40% (Fig. 18). This pattern was observed when the cholesterol 
efflux studies were performed with either NBD-cholesterol (Fig. 18a) or 3H-
cholesterol (Fig. 18b). 
LVB and PB from the Same Patient Showed Different Level of Cholesterol Efflux: 
The cholesterol efflux study was done using PB and LVB from the same 
groups of patients. As mentioned earlier, the cholesterol efflux assay performed 
with PB demonstrated that the group of patients with lower EF showed less 
efficient cholesterol efflux when compared with the group of patients with normal 
EF. However, the cholesterol efflux studies using LVB from both of these groups 
showed very similar cholesterol efflux values [both with NBD-cholesterol (Fig. 18a) 
and 3H-cholesterol (Fig. 18b)] and these values were very close to the efflux 
pattern observed with the PB plasma of the low EF group. Interestingly, the group 
with EF >60% showed higher levels of the cholesterol efflux with their PB plasma 
compared to the LVB. In contrast, the group of patients with EF <40% showed 
similar levels of cholesterol efflux with both, the PB and LVB blood, and the values 
of cholesterol efflux were distinctively much lower than the observed with the PB 
plasma of the normal EF group .There was no significant difference between the 
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cholesterol efflux capacity of LVB plasma used from patients with lower and normal 
EF. 
Plasma Samples with Reduced Cholesterol Efflux Capacity Also Showed Reduced 
PON1 Activity: 
PB and LVB plasma samples from the same groups of patients were used 
to assay plasma PON1 arylesterase activity. Conversion rate of p-NPA to p-
Nitrophenol in a time period of 30 minutes was regarded as measurement of PON1 
activity. The results obtained with the PB plasma showed that patients with normal 
EF had significantly higher PON1 activity compared to patients with lower EF. 
However, similar to the results obtained with the RCT assays, both groups showed 
a very similar pattern of PON1 activity when LVB plasma was used. On the other 
hand, the comparison of PB and LVB plasma from the same group of patients 
showed that PON1 activity was much lower in LVB plasma than in PB plasma in 
the group with EF >60% (Fig.19), whereas PON1 activity varied very little between 
the PB and LVB plasma samples from the group of patients with EF <40%. 
PB Plasma from Control Subjects Showed Much Higher Cholesterol Efflux than 
Both Groups of Patients: 
Cholesterol efflux study was done using plasma from PB plasma collected 
from the control subject group. Following the same method used with the patients’ 
plasma samples, control plasma samples were incubated with foam cells 
containing 3H-cholesterol for 4 hours. The results obtained with the assay showed 
that there was a wide variation in the values of cholesterol efflux among the control 
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group. However, even with the high standard deviation the control group showed 
a significantly higher cholesterol efflux value when compared with the cholesterol 
efflux values obtained with the PB plasma from HF patients with lower EF (Fig. 
22). The cholesterol efflux capacity observed in the PB plasma from the control 
group and the patient group with normal EF (>60%) were not very different. 
Discussion 
The loss of anti-atherogenic functions of HDL has been studied extensively 
in the last few decades. One of the major consequences of the dysfunctionality of 
HDL is impairment of HDL induced cholesterol efflux, clearance of free cholesterol 
and thus RCT. While aging is thought to be responsible for the reduced antioxidant 
activity and RCT capacity of HDL (148), oxidation of HDL and modification of HDL 
during acute inflammatory response have received tremendous attention. Among 
different subpopulations of HDL, HDL3 is believed to have most of the 
cardioprotective functions associated with HDL. HDL3 is most effective in 
stimulating cholesterol efflux from macrophages. Independent studies have 
showed that age-related reduced efficiency and metal-ion induced oxidation, 
hugely impaired the capacity of HDL3 to induce cholesterol efflux (148-150). Loss 
of functionality of HDL is also known to be associated with MPO mediated 
oxidation of apoA-I. Oxidative modification of apoA-I impairs the interaction 
between apoA-I and ABCA1 and the cholesterol efflux is affected. 
Dysfunctionality of HDL often refers to the loss of its antioxidative function. 
Antioxidant properties of HDL, in the context of protecting LDL from oxidative 
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modification, are closely related to the enzymes harbored by or associated with 
HDL. PON1 is an HDL associated enzyme and plays an essential role as an 
antioxidant enzyme. PON1 is secreted from the liver and its interaction with apoA-
I provides stability to this enzyme as HDL acts as the hydrophobic harbor. PON1 
catalyzes hydrolysis of lipid peroxides, fatty acid peroxides and hydrogen 
peroxides to prevent LDL modification (151). HDL associated PON1 prevents the 
oxidation of LDL in several ways- by inhibiting the formation of conjugated dienes, 
peroxides and by decomposing highly cytotoxic aldehydes. Additionally, PON1 
protects HDL itself from oxidative stress (136, 152) and helps HDL to maintain its 
function associated with RCT (136). PON1 is also believed to prevent oxidized 
phospholipid mediated monocyte chemotaxis and macrophage activation (86), 
thiolactone associated endothelial injury and fatty streak formation and improves 
the capacity of HDL to induce cholesterol efflux from macrophages (47, 86). 
Plasma concentration of PON1 is markedly reduced under several pathological 
conditions such as diabetes, hypercholesterolemia and myocardial infarction 
(136). Recent study by Deakin et al (152), showed that oxidation of apoA-I 
associated with HDL impairs the capacity of HDL to stimulate the secretion of 
PON1 from liver and activation of the enzyme. This generates a vicious cycle in 
which PON1 fails to protect HDL from oxidative stress and makes it particularly 
prone to chlorination (152). As a result, HDL becomes less effective as an 
antioxidant and fails to protect LDL from oxidative modification. 
All the patients included in this study were undergoing various routine 
cardiovascular surgeries and were categorized into 2 groups based on their left-
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ventricular EF. Our preliminary results showed that the patients with low left-
ventricular EF had higher Ox-LDL content in their PB plasma when compared with 
the patients with normal EF values (unpublished data). This observation led to the 
hypothesis that HDL functionality would vary between these two groups, as 
oxidative modification of LDL is attenuated by the antioxidative functions of HDL. 
The goal of this study was to evaluate the quality of HDL by performing cholesterol 
efflux assay. 
Foam cells containing fluorescently labeled or radiolabeled cholesterol were 
generated by incubating RAW 264.7 macrophages with cholesterol (unlabeled and 
NBD or 3H-Cholesterol)/ Lyso PtdCho mixed micelles for 18 hours in the presence 
of 40 µM oleic acid (146). Foam cells were incubated with PB plasma from 2 
different groups of patients with low and normal EF for 4 hours and efflux of 
cholesterol was measured. When the assay was performed with foam cells 
containing NBD-cholesterol, we observed that proteins present in the plasma were 
interfering with the measurement of the effluxed NBD-cholesterol. These samples 
were subjected to a deproteination procedure in order to precipitate the protein 
and then the amount of effluxed NBD-cholesterol was measured. As expected, 
cholesterol efflux assay performed with foam cells containing 3H-cholesterol did 
not require any additional treatment before the amount of effluxed cholesterol was 
measured in the medium. However, the results obtained from both of these assays 
were very similar in terms of amount of effluxed cholesterol. The PB plasma from 
the patients with normal range of EF induced approximately 1.5-fold more 
cholesterol efflux than that from the patients with low range of EF (Fig.18). This 
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observation corroborated our previous observation regarding the content of Ox-
LDL present in the PB plasma. 
EF is an indicator of normal functioning of the heart as the EF value refers 
to the amount blood being pumped out of the blood with each contraction. The 
capacity of the heart to pump out the optimum amount of blood can be diminished 
for various reasons and current studies show that HF is common even with 
preserved systolic function or normal EF (153). Chronic heart disease conditions 
are often associated with increased oxidative stress biomarkers such as lipid 
peroxides and malondialdehyde in the blood (154, 155). In accordance to these 
previous findings we observed that PB plasma from the HF patients with low EF 
showed increased sign of oxidative stress than the patients with normal EF. The 
presence of high level of Ox-LDL in the PB of patients with low EF could be 
explained by the compromised quality of HDL. Reduced cholesterol efflux capacity 
of the HDL present in the PB plasma of the group with lower EF indicated the 
possibility of and oxidative modification of HDL. Furthermore, to evaluate the 
quality of HDL a standard PON1 assay was performed. As expected, the PB from 
the group with normal EF showed more than 2-fold increased PON1 activity than 
that from patients with low EF (Fig. 19). This observation not only confirmed our 
initial evaluation regarding the quality of HDL present in the PB, it also explained 
why different amounts of Ox-LDL were present in the blood of these 2 groups. As 
PON1 is known to be the major HDL associated enzyme that protects LDL from 
oxidative modification, the low PON1 activity observed in the PB plasma of patients 
with low EF validated the higher content of Ox-LDL. On the other hand, the PB 
95 
 
plasma from the patients with normal EF showed higher cholesterol efflux capacity 
indicating better HDL functionality, and higher PON1 activity in the corresponding 
plasma corroborated the lower content of Ox-LDL. 
As we expected, the concentration of HDL observed in the plasma of these 
patients did not represent the functionality of HDL. In fact, the average HDL 
concentration found in the patients with low EF (36.3 mg/dL) was slightly higher 
than that found in the patients with normal EF (36 mg/dL). However, when the 
cholesterol efflux capacity and PON1 activity associated with HDL were compared, 
it became clear that patients with normal EF have higher amount of functional HDL 
than that found in the patients with low EF (Table 1.). From this observation it can 
be concluded that the measurement of cholesterol efflux capacity or PON1 activity 
is a much better indicator of HDL quality and functionality than the concentration 














Table 1. Cholesterol Efflux Capacity and PON1 Activity Associated with HDL 
from Patients with Low and Normal EF. 
 
 
Surprisingly, the cholesterol efflux assay and the PON1 assay using the left-
ventricular blood plasma collected from these 2 groups led to equivocal 
conclusions. LVB plasma from both groups showed low cholesterol efflux capacity 
and low PON1 activity. The cholesterol efflux capacity of PB and LVB plasma 











Sample 22 25-30 34 2.23 24.78
Sample 23 30-35 51 2.37 32.77
Sample 26 < 20 Unknown 2.57 31.65
Sample 27 < 20 47 2.89 26.40
Sample 43 35 28 3.37 26.90
Sample 46 23 43 2.83 30.96
Sample 52 20-25 25 3.05 27.53
Sample 53 17 39 3.17 34.71
Sample 56 25 7 2.60 33.15
Sample 58 < 20 Unknown 2.96 29.28
Sample 70 30-35 52 2.76 30.40
Sample 71 23 37 2.58 29.03
Sample 35 60-65 22 5.42 75.00
Sample 37 68 45 4.83 65.45
Sample 42 67 38 4.66 60.58
Sample 50 63 69 5.93 67.29
Sample 44 61 24 5.21 58.18
Sample 55 60-65 25 4.91 71.82
Sample 61 60-65 Unknown 4.78 66.57
Sample 65 60-65 33 5.64 91.95
Sample 67 60-65 42 4.87 76.15
Sample 94 60 47 4.97 75.09
Sample 111 60-65 28 4.88 60.30
Sample 114 60-65 23 5.34 59.43
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20a). The same was true for PON1 activity assay (Fig. 21a). However, the LVB 
plasma collected from the patients with normal EF gave very different profiles of 
cholesterol efflux capacity and PON1 activity when compared with the results 
obtained by using the PB plasma collected from the same group of patients. The 
cholesterol efflux capacity (Fig. 20b) and the PON1 activity (Fig. 21b) in the LVB 
plasma from the patients with normal EF were much lower than those observed in 
their PB plasma, which might indicate that there is more oxidative modification of 
the HDL  in LVB plasma than in PB plasma. This unexpected observation arises 
several interesting questions. Use of PB plasma alone to study cholesterol efflux 
and associated quality of HDL might not be sufficient to predict the cardiovascular 
health of a person. Is there a repair mechanism present in our body that attenuates 
or reverses the oxidative stress related modifications of lipoproteins present in the 
blood circulating in the peripheral tissue? 
It would be interesting to note here that the PB plasma collected from the 
control group subjects showed a much higher cholesterol efflux capacity than that 
from the groups of patients with low EF (Fig. 22). In accordance to our exclusion 
criteria this is not surprising as the control group subjects did not have any history 
of chronic heart diseases. However, to determine the quality of HDL and to 
evaluate the conditions associated with oxidative stress in the control group 
subjects, more studies needed to be performed. The average blood cholesterol 
level found in the control group was much higher (58.25 mg/dL) than either of the 
HF patient group included in the study and can be considered to be in the range 
to have cardioprotective functions. Nonetheless, the cholesterol efflux capacity of 
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the PB plasma from the control group and the group with normal EF were very 
similar even though the concentration of HDL varied widely (average HDL 
concentration in the control group: 58.25 mg/dL and in the HF patient group with 
normal EF: 36 mg/dL). 
Our initial studies indicated that the PB from the patients with low left-
ventricular EF showed elevated sign of oxidative stress when compared with that 
from the patients with normal EF. Further investigation revealed that patients with 
low EF had more amount of dysfunctional HDL in the peripheral and LVB when 
compared with the PB collected from patients with normal EF. Functionality of HDL 
was evaluated by performing cholesterol efflux assay and by assaying PON1 
enzyme activity. All the results taken together, we concluded that patient group 









Figure 18. PB Plasma from the Patients with Lower EF Showed Lower 
Cholesterol Efflux Capacity. 
a) PB and LVB plasma samples from patients with low and normal EF were incubated with 
foam cells loaded with NBD-cholesterol and the efflux of NBD-cholesterol was measured 
following deproteination of the samples; b) PB and LVB plasma samples from the 2 groups 
of patients were incubated with 3H-cholesterol containing foam cells and the efflux of 3H-
cholesterol was measured, CPM values were converted to nmoles of effluxed cholesterol. 
Cholesterol efflux associated with PB plasma from patients with normal EF was compared 
with that from patients with low EF. Similarly, cholesterol efflux associated with the LVB 
plasma from the 2 groups were analyzed. All the samples were analyzed in triplicates and 
values are expressed as mean ± SD (n ≥ 3). *** < 0.005 (one-way ANOVA with 






Figure 19. PB Plasma from the Patients with Normal EF Showed Higher PON1 
Activity. 
PB and LVB plasma samples from patients with low and normal EF were analyzed for HDL 
associated PON1 enzyme activity and the conversion of p-NPA to Nitrophenol was measured by 
reading absorbance at 410 nm. PON1 activity associated with PB plasma from patients with normal 
EF was compared with that from patients with low EF. The comparison of PON1 activity related to 
LVB plasma between the 2 groups was done similarly. All the samples were analyzed in triplicates 
and values are expressed as mean ± SD (n ≥ 3). *** < 0.005 (one-way ANOVA with Bonferroni’s 







Figure 20. Peripheral and LV Blood Plasma from the Same Patient with Low 
EF and/ or Normal EF were Compared in Terms of Capacity of Cholesterol 
Efflux. 
a) 3H-cholesterol efflux associated with peripheral and LVB plasma from the patient group with low 
EF were measured and cholesterol efflux capacity of the PB plasma and the LVB plasma taken 
from the same patient was compared; b) Similarly, cholesterol efflux induced by the PB plasma and 
the LVB plasma from the patients in the normal EF group were compared. All the samples were 






Figure 21. PON1 Activity Associated with the PB Plasma and the LV Blood 
Plasma were Compared for each Patient Belonging to either Low or Normal 
EF Group. 
a) PON1 activity related to the PB plasma and the LVB plasma was compared for each patient in 
the low EF group; b) Similarly it was done for the patients belonging to the normal EF group. All the 







Figure 22. Cholesterol Efflux Capacity Associated with Control Group with 
No History of Chronic Heart Disease and Patients Groups with Low and 
Normal EF were Compared. 
PB plasma from the control group and the peripheral and LV blood plasma samples from the 2 
groups of patients were incubated with 3H-cholesterol containing foam cells and the efflux of 3H-
cholesterol was measured. Cholesterol efflux associated with the PB plasma from the control group 
was compared with peripheral and LVB plasma from patients with low and normal EF respectively. 
All the samples were analyzed in triplicates and values are expressed as mean ± SD (n ≥ 3). *** < 






CHAPTER 4: CONCLUSION AND DISCUSSIONS 
Lipoproteins which are intricately associated with atherosclerosis play 
crucial roles in the formation or regression of atherosclerotic plaque. While high 
levels of plasma LDL are directly related to the risk of increased plaque burden, 
the relationship between HDL and the regression of the plaque burden is more 
complex. Increased concentration of plasma LDL leads to the initiation of a series 
of events which are pro-inflammatory in nature. Secretion of pro-inflammatory 
factors and cytokines stimulate differentiation of the monocytes to the adherent 
macrophages and expression of SRs. Modified LDLs, such as Ac-LDL or Ox-LDL 
act as ligands for these SRs and the uptake of modified LDLs by SRs or other 
mechanisms starts the events leading to atherosclerotic plaque formation. 
Macrophages loaded with unesterified and esterified cholesterol, known as foam 
cells, are the key components of these plaques. To study various aspects of 
atherosclerotic plaque development and RCT, foam cells are regularly generated 
in vitro. In vitro generation of foam cells traditionally involves incubation of 
macrophages with Ac-LDL or Ox-LDL probed with radiolabeled cholesterol. 
However, as described in the chapter 2, there are several drawbacks associated 
with the use of isolated and modified LDL, used for this purpose. One of the most 
important restraints of this technique is its limited use in the clinical set up. As 
described before, LDL is hard to isolate and even harder to store for long time 
without causing unwanted modifications to the lipoprotein. Thus, developing an 
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assay technique which can used in the doctors’ office or diagnostic clinic is really 
hard when LDL is used to generate foam cells. 
RCT is a unique defense mechanism of our body that prevents or restricts 
atherosclerotic plaque formation. HDL is the key player involved in RCT. HDL with 
or without the help of transporters and receptors induce efflux of cholesterol from 
macrophage foam cells and delivers the cholesterol to the liver for excretion. 
Studies from several independent laboratories in the last decades of the 20th 
century strongly established the inverse relationship between HDL and 
cardiovascular diseases. Initially it had been thought that the quantity of plasma 
HDL is the most important indicator to diagnose CAD and the higher is the 
concentration of plasma HDL, less are the chances of atherosclerotic plaque 
development. However, the last few years of research indicated that the 
relationship between HDL and atherosclerosis is much more complex. 
HDL can be considered as the ‘guardian angel’ which often multi-tasks to 
protect the cardiovascular health of our body. Apart from inducing cholesterol efflux 
and preventing plaque formation, HDL prevents oxidation of LDL and exerts anti-
inflammatory, anti-apoptotic and anti-thrombotic effects. In other words, if LDL is 
called pro-atherogenic, HDL can definitely be referred as anti-atherogenic in 
function. Nonetheless, the anti-atherogenic properties of HDL are closely 
associated with the quality of this lipoprotein and not its quantity in the serum. 
Oxidation of HDL renders it dysfunctional and often pro-atherogenic. Ox-HDL fails 
to prevent LDL oxidation and is less effective in inducing cholesterol efflux from 
the foam cells. Oxidation of HDL is associated with the oxidation of its major 
106 
 
apolipoprotein, apoA-I, the oxidation of its anti-oxidant enzyme PON1 and often 
the displacement of apoA-I or PON1 with SAA. While the quantification of PON1 
or SAA gives an indirect evaluation of the quality of HDL, measuring the efficacy 
of cholesterol efflux in the presence of HDL is the most direct approach to 
determine HDL quality. 
For the last several years, different approaches have been taken to quantify 
cholesterol efflux or RCT and assess the quality of HDL from subjects with or 
without the history of CAD. No matter what the approach is, these studies start 
with the generation of in vitro foam cells. In this study, we intended to develop an 
assay which can quickly and effectively measure cholesterol efflux from foam cells 
using patients’ plasma samples. Furthermore, our goal was to develop an assay 
which can be used in the doctors’ office or in the diagnostic labs very efficiently 
without compromising the quality of the results. 
The longest and very tedious step in foam cell generation is the isolation of 
LDL. Our goal was to enrich macrophages with free or esterified cholesterol in a 
faster and more efficient way. To overcome the biggest obstacle of solubilizing the 
highly hydrophobic cholesterol in aqueous solution, we have used Lyso PtdCho. 
Lyso PtdCho is an amphiphilic biological detergent which has been used by our 
laboratory before to enrich cells with highly non-polar β-carotene. We manipulated 
this technique further to deliver cholesterol or CE to the macrophages. We 
established that the foam cells generated by this technique were physiologically 
relevant by doing lipid droplet staining and quantifying the accumulation of 
cholesterol in the total lipid fraction and CE fraction. These foam cells were also 
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enriched with fluorescently labeled or radiolabeled cholesterol. We further 
established that micelle mediated foam cells generation is a highly reproducible 
technique. 
One of the crucial drawbacks for Ac-LDL or Ox-LDL generated foam cells 
is the instability of the reagent. Ac-LDL or Ox-LDL are highly unstable and need to 
be used within 4-5 days since isolation. We showed that the micelles containing 
cholesterol (unlabeled and labeled) and Lyso PtdCho were highly stable at 4°C 
and -20°C for more than 4 weeks. It was further established that foam cells 
generated with stored micelles are qualitatively and quantitatively similar to the 
ones generated with freshly prepared micelles. 
The generation of foam cells with mixed micelles was not a cytotoxic 
technique. Lyso PtdCho, which is a cytolytic detergent, was metabolized into non-
cytotoxic PtdCho during micelle uptake by the macrophages. Unlike Ac-LDL or Ox-
LDL mediated foam cell generation, micelle mediated foam cell development was 
completely independent of SR associated uptake. It is important to mention that 
generation of foam cells with mixed micelles is a very rapid technique and the cells 
were enriched with unlabeled and labeled cholesterol within 4-6 hours of 
incubation with the micelles. For the diagnostic screening purpose it would be 
crucial as the whole assay can be completed within 12 hours starting from the 
preparation of mixed micelles. We utilized the micelle generated foam cells to 
evaluate the cholesterol efflux induced by native and Ox-HDL. As expected, 
cholesterol efflux induced by native HDL was much higher in quantity when 
compared with the same concentrations of Ox-LDL associated cholesterol efflux. 
108 
 
Based on this observation, we hypothesized that these foam cells could be 
further utilized to screen patient samples to identify subjects with high or low level 
of Ox-HDL. Samples from human subjects with no history of CAD were used as 
the control group. The 2 other groups of patient samples belonged to human 
subjects undergoing routine cardiovascular surgeries [coronary artery bypass 
grafting (CABG), valve repair/replacement (AVR, MVR, TVR: aortic, mitral, or 
tricuspid valve replacements) or other open heart surgeries]. Among these, one 
group of patients had normal range (55-70%) of left-ventricular EF, while the other 
group had clinically defined low range (<40%) of left-ventricular EF. 
Our preliminary studies revealed that the patient group with low EF showed 
higher level of Ox-LDL in the blood plasma when compared with that with normal 
EF. As HDL protects LDL from oxidation and oxidized status of LDL is closely 
associated with the quality of HDL, we decided to evaluate the quality of HDL by 
performing cholesterol efflux assay using micelle mediated foam cells. The 
cholesterol efflux study clearly showed that the amount of cholesterol effluxed from 
the foam cells in presence of plasma from patients with normal EF was much 
higher than in the presence of plasma samples from the group with low EF. On 
average the efflux of cholesterol upon incubation of foam cells with PB plasma 
from patients with normal EF was ~1.6 fold higher. However, the amount of 
effluxed cholesterol from the foam cells after incubating with PB plasma from the 
control group showed a significantly higher value than the rest of the groups. We 
concluded that the patients with low EF had a higher level of dysfunctional or Ox-
HDL in their PB as the plasma failed to induce efficient cholesterol efflux when 
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compared with the control group or the patient group with normal EF. We further 
concluded that patients with normal range of EF have lower level of Ox-HDL in 
their PB. 
To evaluate the quality of HDL we further performed PON1 assay. PON1 
assay is another indirect method to investigate the quality and the functionality of 
HDL beside the measurement of Ox-LDL. The results from PON1 assay clearly 
reflected our previous observation. Patients with low EF showed lower PON1 
activity in the PB plasma when compared with the patients with normal EF. As 
inactivation of PON1 can be a direct consequence of oxidation, which indicates 
oxidation of HDL, estimation of PON1 activity further elucidates the quality of HDL. 
However, left-ventricular blood plasma from both groups of patients showed low 
level of cholesterol efflux, low PON1 activity and high level of Ox-LDL. This finding 
was surprising for the group with normal EF range as the left-ventricular blood 
plasma appeared to have more Ox-HDL than their PB plasma. 
This project was designed to develop a quick and efficient assay to measure 
and evaluate the quality and functionality of HDL. Our goal was to develop a 
screening assay which can be utilized by the doctors’ office or by diagnostic clinics 
to screen a large number of patient samples to evaluate the efficiency of their RCT. 
We successfully generated physiologically relevant in vitro foam cells and utilized 
them to screen patient samples to evaluate the quality of HDL. This novel 
technique is highly reproducible and reliable. 
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This novel technique of delivering macromolecules to the cells can be 
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